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ABSTRACT
The ultimate goal of tissue regeneration is to replace damaged or diseased tissue
with a cell-based or biomaterial-based tissue that accurately mimics the functionality,
biology, mechanics, and cellular and extracellular matrix (ECM) composition of the
native tissue. Specifically, the ability to control the architecture of tissue engineered
constructs plays a vital role in all of these issues as scaffold architecture has an affect on
function, biomechanics, and cellular behavior. Many tissue engineered scaffolds focus
on the ability to mimic natural tissue by simulating the ECM due to the fact that in each
distinct tissue, the ECM serves as a structural component by providing unique
mechanical strength as well as regions for cellular attachment or the storage of a variety
of biomolecules. Additionally, cellular behavior has the ability to be controlled based on
the structure and composition of the ECM. More specifically, matrix has the ability to
modulate a variety of cellular behaviors such as: adhesion, morphology, migration,
proliferation, and differentiation while also controlling the ability of cells to produce and
synthesize ECM with similar characteristics to that of surrounding tissue. Tissue matrix
and structure plays an essential role during the process of tissue formation, remodeling,
and regeneration.
The ability to mimic native tissue ECM using various biofabrication-based
techniques has become an emerging concept in the realm of tissue regeneration.
Biofabrication utilizes automated computer-aided-design (CAD) and computer-controlled
technologies to create reproducible biomaterial and cell-based scaffolds that have the
ability to imitate native tissue ECM. Of particular interest are strategies that employ
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biofabrication with the aim of improving the overall control over scaffold architecture
and microstructure while also providing reproducibility.
Due to their versatility, a variety of promising biofabrication strategies exist,
including rapid prototyping methods such as bioprinting and additive manufacturing,
which rely on the deposition or extrusion of materials. Using these methods, a multitude
of materials can be easily used to fabricate scaffold structures with various morphologies.
However, the potential of many biofabrication methods in tissue engineering applications
is limited by the potential resolution of the structures that can be created. It was our goal
to investigate a unique biofabrication strategy with the aim of fabricating 3-D scaffolds at
a high resolution with morphological, biological, and mechanical properties similar to
those of natural intervertebral discs (IVDs).
Initially, a CAD-based biofabrication approach was developed and systematically
optimized. This method was selected to utilize a custom-designed computer interface
with 3-D motion control that allowed for greater resolution and precision of the
fabricated scaffold architecture. Furthermore, we incorporated a temperature controlled
polymer collection stage, which proved advantageous in enhancing the resolution of the
biofabrication technique. By lowering the temperature of the collecting stage below the
freezing point of the polymer solution, it was discovered that the extruded polymer
solution could be solidified directly as it exited the micropipette extrusion tip through an
increase in viscosity.

Results from initial studies provided valuable clues towards

determining the relationship between motor speeds, polymer solution temperatures,
micropipette size, extrusion rate, and polymer solution viscosity.
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These results

encouraged the investigation of the ability to use this method to precisely control scaffold
spatial orientation for the fabrication of IVD scaffolds.
Since previous IVD scaffold fabrication methods have not effectively accounted
for the inadequacies of spinal fusion and artificial disc replacement in the treatment of a
degenerated disc, we addressed the significance of matching native tissue histology and
biomechanics by using fabricated scaffolds that closely mimic natural IVD tissue. The
annulus fibrosus (AF), or outer region of the IVD, was the focus of this project due to
current and previous challenges in recreating its discrete tissue architecture, which is not
an issue for the inner nucleus pulposus (NP) region, as it is more commonly mimicked
with the use of a hydrogel-based biomaterial.
Multiple elastomeric materials, including biocompatible and biodegradable
polyurethane (PU) and chitosan-gelatin (CS/GEL), were investigated to evaluate the
usefulness of this biofabrication approach to create biomimetic IVD scaffolds utilizing
various materials. It was determined that the biofabrication method enabled the use of
multiple materials and that the fabricated scaffolds were able to mimic the kidney shaped
structure of the IVD. Additionally, the scaffolds exhibited ideal concentric lamellar
thickness and spacing, accurately mimicking the native structure of the AF in the human
IVD. To the best of our knowledge, these accomplishments in recreating the native AF
histological architecture within tissue engineered constructs have not been achieved
elsewhere. Cells attached and aligned on the scaffolds in the direction of the concentric
lamellar structure, emulating cell behavior comparable to the native AF. These 3-D
scaffolds exhibited ideal elastic properties and did not experience permanent deformation
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under dynamic loading. Additionally, the scaffold mechanical properties showed no
significant differences when compared with native human IVD tissue. The scaffolding
promoted chondrocyte cell attachment and proliferation in alignment with the concentric
lamellae, proving this method improves upon current IVD scaffold fabrication
approaches, as it takes into account native tissue structure and cell response.
To expand upon these findings, the biomimetic IVD scaffolds were investigated
to analyze the formation of 3-D cellularized tissue. 3-D multicellular spheroids formed
from chondrocytes were incorporated within the scaffold to fully cellularize the void
spacing within the IVD scaffold lamellae. The ability of this 3-D cellularized structure to
emulate native IVD tissue was then further analyzed by evaluating the ability of the
scaffolds to synthesize matrix that was structurally and compositionally similar to that of
native tissue. Our studies indicate that the 3-D cellularized IVD constructs accurately
mimic native IVD tissue and provide not only a scaffold, but a cellularized platform to
promote tissue regeneration. Future studies will assess the biofabricted IVD structures
for tissue regeneration and biostability using in vivo rodent subcutaneous animal models.
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CHAPTER 1
1. INTRODUCTION

1.1 Intervertebral disc (IVD) Degeneration
Intervertebral disc (IVD) degeneration is characterized by the deterioration of the
disc tissue. This deterioration is characterized by unique disorganization of extracellular
matrix (ECM) within each portion of the IVD. In the inner region of the disc, the nucleus
pulposus (NP), proteoglycan (PG) content decreases.

In the outer disc region, the

annulus fibrosus (AF), the organized lamellar collagenous structure begins to weaken.
With a decrease in PG content, the inherent water content of the disc reduces. This
dehydration within the NP is accompanied by a loss in disc height, and a subsequent
decrease in swelling pressure. Further, as the organized AF structure deteriorates, it
becomes less stable and begins to tear. This tearing within the AF prevents the annulus
from containing the swelling pressure from the NP. The combination of a loss in PG
content in the NP and a tearing of the collagenous lamellae in the AF, the disc
degenerates and begins to fail in its duty to support spinal loading. This degeneration is
accompanied by a loss in disc height, resulting in compression of the spinal nerves, which
causes intense back pain for patients, and is oftentimes the underlying cause for patients
to seek medical intervention.
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1.2 Clinical Intervention Strategies
Initially, patients with a degenerated IVD are treated with rest, therapy, and medication.
Usually, these therapeutic remedies ameliorate the pain and other issues such as resulting
disabilities. However, when these therapies prove ineffective, surgical intervention is
necessary. Discectomy, or removal of the degenerated portion of the IVD, is often the
first step towards relieving a patients symptoms. Alternatively, patients can undergo
spinal fusion to immobilize the degenerated region of the spine, which helps to
temporarily relieve pain. However, fusion does not restore disc function or patient
mobility and prevents natural biomechanical forces on the spine, possibly leading to
further disc degeneration.
Recently, patients have also been given the option of replacing the IVD with a
artificial disc replacement, which have been used in Europe for over a decade and are
recently gaining interest and clinical approval in the United States. However, there are
some downfalls to these current disc replacements. Though they aid in the preservation
of motion as well as disc height, they do not replicate physiologic motion or absorb
compressive forces as their composition is mostly rigid polymeric and metallic materials.
Due to this composition, these implants may also produce wear particles and cause
osteolysis. Furthermore, current implants exhibit significant differences in compliance
from that of the native tissue, which may cause stress shielding and subsequent implant
migration into the vertebral bodies. Although these current clinical interventions alleviate
some symptoms of disc degeneration, they do nothing to address the underlying cause of
the degenerated disc tissue itself, and often lead to further disc degeneration at adjacent
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vertebrae levels. Due to the problems associated with these conventional approaches for
IVD degeneration, tissue engineered constructs are now being investigated, as they offer
exceptional opportunities to improve overall patient satisfaction and well being by
promoting tissue repair.
1.3 IVD Tissue Regeneration
Tissue engineering, which is oftentimes referred to as regenerative medicine, is an
interdisciplinary field that incorporates ideas from: biology, chemistry, materials science,
engineering, and medicine.

Using a combination of these disciplines, therapeutic

methods to promote regeneration of many tissues of the body, including the IVD, are
being investigated by researchers worldwide, including cell-based therapies, signaling
molecule therapies, and biomaterial-based therapies. These approaches are often used in
combination, as biomolecule and cell-based therapies alone may prove ineffective in
supporting spinal loading.

A biomaterial structure is likely necessary to provide

mechanical stability and support loading throughout the IVD regeneration process, as
well as provide guidance for cell growth and new ECM organization. For these reasons,
biomaterial scaffolds should have similar overall structures and mechanics to that of the
native tissue. Additionally, scaffolding constructs provide the ability to incorporate and
deliver signaling molecules which often enhance the success of the regenerated construct.
A major goal of tissue engineered constructs is to mimic the targeted tissue’s
ECM structure and composition with a biomaterial scaffold. Through mimicry of ECM,
a biomaterial scaffold provides a platform for the guidance of cellular orientation. As
scaffolds with a defined structure can control cell morphology, they subsequently control
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ECM deposition, including both the type and organization of the synthesized matrix.
Further, desirable mechanical properties similar to that of native tissue can be achieved
by controlling ECM composition and orientation on a tissue scaffold.
1.4 Limitations
Tissue engineering serves as a promising alternative to the current treatment
options available for patients requiring surgical intervention due to a degenerated spinal
disc. Tissue engineered IVDs may offer the advantage of motion preservation and disc
space restoration. However, to date, researchers have not created an IVD tissue scaffold
that accurately mimics the native tissue histology in combination with similar
biomechanics of the natural IVD tissue. In order to engineer a normal IVD structure, the
materials and structures to be used for IVD tissue regeneration must mimic the 3-D
histological architecture of the native IVD, which will promote the formation of
organized cellular and extracellular structures similar to that of native IVD tissues. The
close correlation between the biological functions and the molecular compositions of the
disc structures strongly suggests that a major task of IVD regeneration is to create
scaffolds that precisely reproduce the structural, biological, and mechanical functions of
the disc structure and organize them in a spatial manner similar to that of the native disc.
Many researchers have attempted to recreate the IVD, but the discrete tissue architectures
of the NP and AF have posed great challenges. Furthermore, the biological functions,
microstructures, and mechanical properties of current scaffolds are far from satisfactory,
perhaps due to the poor ability to control scaffold architecture during fabrication.
Although current approaches focused on IVD tissue regeneration are far from
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satisfactory, the results from these studies help to provide a platform towards the creation
of a successful and clinically-relevant approach to regenerate IVD tissue. Based on the
previous successes and failures in tissue engineering IVD scaffolds, we have developed a
unique strategy attempting to further advance IVD tissue engineering.
1.5 Project Objective, Significance, and Innovation
The objectives of this research were to use bioengineering strategies to pursue the
development of materials and methods to imitate the IVD and facilitate tissue
regeneration. To this end, our aims were to use a biofabrication technology to create
reproducible scaffolds that mimicked the lamellar microstructure of the AF in native IVD
tissues.

We believe that this biomimetic approach will promote the formation and

synthesis of ECM more similar in composition, organization, and mechanics to that of
native tissue, therefore providing a more feasible approach towards regenerating IVD
tissue.
The degenerated spinal disc is one of the most expensive medical issues currently
encountered, as it results in the disability of many people within the aging population.
This project has the potential to significantly impact worldwide healthcare goals
involving the restoration of native IVD tissue by decreasing its economic burden and
impact on society. The ultimate goal in tissue engineering an IVD is to replace the
degenerated disc tissue with a functional scaffold that will promote the growth of new
tissue while also maintaining natural motion and load bearing abilities.

More

specifically, the strategies described in this work may aid in the promotion of native
tissue formation to ultimately treat the problems associated with IVD degeneration rather
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than conventional clinical approaches, which focus only on relieving the symptoms. The
aims proposed within this project will generate conceptual advances in understanding
IVD biomaterial and scaffold implant design criteria, leading to increased technical
knowledge for the development of a new clinically relevant IVD replacement.
1.6 Specific Aims and Rationale
Aim 1: To develop a biofabrication approach that would allow for the creation of IVD
scaffolds with precise control of scaffold structure.
Rationale: Current methods focused on creating IVD scaffolds are limited in their ability
to accurately mimic native IVD structure. To this end, we believe that utilizing a
computer-controlled polymeric extrusion-based biofabrication approach will enable IVD
scaffolds to be created with distinct architectures. Our hypothesis is that this type of
device, along with the incorporation of a temperature-controlled collection mechanism,
would allow for the increase of the viscosity of the polymer solution in order to solidify
precise structures directly upon deposition.

Aim 2: To fabricate tissue engineered scaffolds with structural and mechanical properties
highly similar to native IVD tissue.
Rationale: We hope to use our biofabrication approach to create IVD scaffolds with the
precise characteristics of the native IVD tissue. Specifically, we want to mimic the IVD
shape, concentric lamellar structure, lamellar spacing, and its biomechanical properties.
It is our hypothesis that our unique biofabrication approach will facilitate in the
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fabrication of complex scaffolds with highly similar biomimetic characteristics of the
native IVD tissue.

Aim 3: Evaluate the tissue regeneration capabilities of the biofabricated IVD tissue
engineered scaffolds in vitro.
Rationale: Elastic lamellar-based scaffolds will be assessed for their potential as suitable
structures for IVD tissue regeneration. It is our hypothesis that our constructs will exhibit
desirable characteristics while demonstrating potential as functional IVD scaffolds for
tissue regeneration.

1.7 Organization of Dissertation
The following manuscript is arranged into different chapters that showcase
individual studies relating to the overall aims of the project.

In Chapter 2, a

comprehensive literature review is presented. This chapter focuses on the specifics of the
IVD structure, the causes and results of disc degeneration, current methods available to
repair a degenerated disc, and lastly, different methods and techniques that have been
explored for tissue regeneration of the IVD. Emerging tissue engineered scaffolds and
techniques for IVD regeneration are discussed in detail. Overall assessments of these
current strategies to enhance IVD tissue regeneration are provided, specifically focusing
on in vitro and in vivo analyses.

Chapter 3 provides the results from the first

investigation into our unique biofabrication strategy, which was aimed at creating
biomimetic IVD scaffold structures. The results of this experiment proved the ability of
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the biofabrication method to precisely control polymer extrusion at a high resolution
while also providing the initial platform towards mimicking IVD shape and structure.
Mechanical properties of the scaffolds were also investigated to ensure elasticity of the
constructs. In Chapter 4, the previous findings are further elaborated upon, showing that
this novel IVD biofabrication method can utilize multiple polymeric biomaterials in the
creation of IVD scaffolds.

The ability of the scaffolds to mimic lamellar and

interlamellar spacing as well as the scaffolds’ ability to control cellular morphology
similarly to native tissue is discussed. Finally, it was demonstrated that the biomimetic
scaffolds have similar mechanical properties when compared to native IVD tissue. In
Chapter 5, a 3-D cellularized version of the scaffold discussed in previous chapters was
fabricated. It was demonstrated that IVD constructs could be cellularized within the
voids of their lamellar structure using multicellular spheroids. Additionally, cellular
morphology, as well as ECM synthesis were analyzed and compared to native IVD
tissue. Chapter 6 summarizes overall conclusions drawn from the body of work and
discusses challenges and future directions related to the progress of the presented
research.
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CHAPTER 2
2. INTERVERTEBRAL DISC (IVD): STRUCTURE, DEGENERATION, REPAIR,
AND REGENERATION

2.1 Introduction
Over 80% of the adult population experiences low back pain at some point in their
lives, resulting in $90 billion in annual costs to alleviate and treat this pain

1-4

. The

degeneration of the intervertebral disc (IVD) is thought to be the primary cause of low
back pain, causing compression of the spinal nerves and adjacent vertebrae. It is difficult
to pinpoint the exact cause of degeneration, but it is thought that many confounding
factors may play a significant role in the degenerative process.
The IVD is a tough tissue structure sandwiched between the vertebral bodies
(Figure 2.1). It has three functions including: 1) acting as a ligament to hold the vertebrae
of the spine together; 2) a shock absorber; and 3) a “pivot point” that allows the spine to
bend, rotate, and twist. There are three distinct structures in the IVD: the nucleus
pulposus (NP), the water-rich gelatinous center that primarily bears the pressure; the
annulus fibrosus (AF), the collagen-rich fibrous structure of ~15-25 concentric sheets of
collagen (lamellae) that confines the pressurized NP; and the vertebral end-plates (VEP),
which are cartilaginous plates that are interwoven into the AF at the disc-vertebrae
interface and supply nutrients to the disc. All three of the IVD structures contain
chondrocyte-like disc cells. The NP contains large concentrations of negatively charged
proteoglycans (PGs), which cause the NP to retain water and maintain its swelling
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pressure

5,6

. PGs help to maintain water content and swelling pressure in the IVD and

intertwine in a lose network of collagen type II fibers

5,7,8

. The AF has a lamellar

structure composed of collagen type I and II fibers. This lamellar architecture helps
maintain the tensile properties of the disc while providing structural support for PG
synthesis 9.

Figure 2. 1: MRI of IVD showing NP and AF in distinct regions (left). Schematic of
spinal column (middle). Anatomy of normal disc with histological stain (right) 10-12.
Current treatments to help alleviate low back pain due to IVD degeneration
include rest and medication. However, when these methods do not suffice, patients must
undergo procedures for a spinal fusion or an artificial disc replacement. Spinal fusion
helps to temporarily relieve pain, but does not restore disc function and prevents natural
biomechanical forces on the spine. This possibly leads to further degeneration at adjacent
levels 13. Therefore, fusion is not ideal as it sacrifices natural motion and may exacerbate
the problem of further degeneration down the road. An alternative to spinal fusion is an
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artificial disc replacement, which has been used in Europe for over a decade and is
recently gaining interest and clinical approval in the United States

14,15

. Current disc

replacements aid in the preservation of some natural motion as well as disc height, but
they do not absorb compressive forces as their composition is mostly rigid metallic
materials. Also, these implants produce wear particles and may cause osteolysis

16

. In

addition, current implants exhibit significant differences in compliance from that of
native tissue, which may cause stress shielding and subsequent implant migration into the
vertebral bodies. Because of the problems associated with these conventional approaches,
tissue engineered constructs may help promote integration of natural tissue while
preserving natural kinematics, disc height, and the ability to absorb compressive forces.
Successfully tissue-engineered IVD tissue must have the native IVD histological
and macro structures. Therefore, in order to engineer normal IVD structure, the materials
and structures to be used for IVD tissue engineering must mimic the 3-D architecture of
native IVD to promote the formation of organized cellular and extracellular structures
similar to that of native IVD tissues. The scaffolds must allow the infiltration of nutrients
and removal of wastes to maintain cell viability. The close correlation between the
biological functions and the molecular compositions of the disc structures strongly
suggests that a major task of IVD regeneration is to create scaffolds that precisely
reproduce the structural and biological functions of disc structure and organize them in a
spatial manner similar to that of native disc. Many researchers have attempted to recreate
the IVD, but the unique composition and structure of the disc has posed great challenges.
Furthermore, the biological functions, microstructures, and mechanical properties of
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current scaffolds are far from satisfactory. The ultimate goal in tissue engineering an IVD
is to replace the degenerated disc tissue with a functional scaffold that will promote the
growth of new, healthy tissue while also maintaining the motion and load bearing
abilities and preventing adjacent disc degeneration.
2.2 IVD Structure
The IVD is a complex joint which permits flexible motion within the spine while
serving as a shock absorber. The purpose of the disc is to allow 3-D motion, but also to
prevent excessive motion and maintain mechanical stability. There are 3 main
components within the IVD: the NP, AF, and VEP. The NP consists of the soft center
within the spinal disc, while the outer portion of the disc which surrounds the NP is
referred to as the AF. The VEP is composed of fibrocartilage and surrounds the disc on
the top and bottom and separates the IVD from the spinal vertebrae.
IVDs are composed of cartilage, making regeneration difficult because it is an
avascular tissue. Due to its avascular nature, nutrient transport and waste removal is a
much more complicated process relying solely on diffusion across the VEP and within
the disc matrix 17-19. The IVD is the largest avascular tissue in the human body, with only
the peripheral portion of the tissue containing a blood supply. Similarly, there is a lack of
nerves as well. Some nerve extensions innervate the periphery of the spinal disc, but the
majority of the disc is not innervated. It is thought that compression of the nerves on the
periphery of the disc is responsible for a patient’s perceived pain as the disc degenerates.
A large problem in nutrient and solute transport is the calcification of vertebral endplates
which occurs as the disc degenerates. If nutrients are not provided to disc cells and waste
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products are also not removed, then these waste products linger in the matrix of the disc
preventing the maintenance of healthy IVD chondrocytes.

Decreased nutrition

accompanied with a loss in PG and water content significantly depletes the ability of IVD
cells to function properly. Subsequently, disc degeneration occurs if nutrition is depleted
or impeded. Oxygen concentration gradients change across the cross section of the disc,
decreasing towards the center as the peripheral cells use the oxygen first 20. Opposite the
oxygen gradient is the lactate gradient, which is greater in the disc center

20

. The low

oxygen and high lactate concentrations in the NP create an acidic environment where the
amount of PG may be subsequently decreased

21

. Because the IVD is in a nutrient

deficient environment, only a small amount of cells can survive. By tissue standards, the
IVD contains a low cell density, with most of the tissue composed predominately of
ECM molecules. The main function of cells within the IVD is to constantly secrete ECM
in order to maintain a stable tissue. As matrix is constantly synthesized, it is also being
degraded which ensures that the ECM remains a structured environment. This ECM
consists mostly of PGs, highly concentrated and negatively charged molecules that
increase the water content, as well as a variety of different collagen molecules which
promote the strength of the AF 5. The most prevalent types of collagen are collagen types
I and II, which make up 80% of the collagen composition within the disc. However,
collagen types III, V, VI, IX, and XI are also present to help organize the disc into its
lamellar structure 22.
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2.2.1 Nucleus Pulposus (NP)
The NP is a gelatinous structure consisting of a large amount of PGs or aggrecans
with sparsely arranged collagen fibrils serving as supporting matrix (Figure 2.2). PGs, a
major matrix component, are glycoproteins containing a protein core and at least 1
glycosaminoglycan (GAG) chain
containing hyaluronan (HA)

23

22

. The PGs are similar to articular cartilage, also

. Because PGs, and more specifically GAGs, are

hydrophilic, they maintain a large quantity of water in the IVD. The high concentration of
GAGs increases the osmotic pressure of the NP and allows it to swell and resist large
compressive loads 24-26. It is believed that decreasing the amount of GAGs will decrease
the disc height and cause disc degeneration as the NP becomes more fibrous. Normal,
healthy discs represent a changing profile of inhomogeneous material across the disc with
GAG and water content increasing towards the disc center 27. The purpose of the NP is to
resist compressive forces and evenly redistribute the forces within the spine. While PGs
make up roughly 50% dry weight of the NP, the NP is also composed of 25% collagen
22,28,29

. Collagen type II is highly prevalent in the NP as its concentration decreases

towards the peripheral AF

22

. Each of these molecules aid in the regulation of growth

factors, therefore controlling cellular metabolism.
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Figure 2. 2: Schematic showing different regions of the IVD and their composition and
structure (top). Fluorescent imaging showing different cell morphology in different
disc regions (bottom) 11.
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Though the ECM is the main component of the NP, it also contains around 4x106
cells/ml 22. The cells are mostly chondrocytes and are more rounded as compared to cells
in the AF (Figure 2.2) 30. NP cells also develop a larger cytoplasm and a more complex
structure than AF cells

31

. Characteristic markers for chondrogenic expression of NPs

include collagen types II and IX, aggrecan, and SOX9 32-35.
2.2.2 Annulus Fibrosus (AF)
The IVD is largely heterogeneous and exemplifies great differences between the
NP and the AF (Table 2.1). The AF and NP are separated by what is called the transition
zone 36. The AF is present to withstand the tension created during NP deformation. The
AF is composed of more than 2/3 collagen, where PGs make up only a small percentage
of its composition

22,28,37

. The AF can be separated into the inner AF and the outer AF.

The outer AF contains an oriented lamellar array of densely packed collagen fibers, while
the inner AF is similar to the outer portions except it is not as dense and the oriented
lamellae are not as organized 22. Collagen type I is highly prevalent in the outer AF, while
its concentration decreases towards the NP

22

. The AF has a multilayered, oriented

lamellar structure with concentric layers creating a regular pattern of collagen type I
fibers (Figure 2.2)

38

.

The collagen fibrils are oriented concentrically with each

subsequent layer oriented 60° to the spinal column. As the outer AF moves inward and
approaches the NP, the orientation of the concentric lamellae gradually changes from
angles of 62° to 45° 39.
The AF contains roughly 9x106 cells/ml. Cells within the AF resemble fibroblasts,
showing a thin elongated structure oriented parallel to the collagen fibers within the
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concentric lamellae (Figure 2.2). The NP and inner AF contain only chondrocytes, while
the outer AF contains mostly fibrochondrocytes 40.

Table 2. 1: Difference in IVD composition and mechanical properties between the
annulus fibrosus and nucleus pulposus 41-50.
Water (per weight)
Collagen (per dry weight)
Proteoglycans (per dry weight)
Other Proteins (per dry weight)
Compressive Modulus (MPa)
Tensile Modulus (MPa)

Outer AF
65-75%
75-90%
10%
5-15%
AF
0.116-2.3
0.2-136

Inner AF
75-80%
40-75%
20-35%
5-40%

NP
75-90%
25%
20-60%
15-55%
NP
0.003-.031
N/A

As the majority of artificial disc replacements are performed on the lumbar spine,
this review will focus on that region. Although, spinal disc composition does not seem to
be significantly affected by the discs level within the spine, the size of the IVD increases
inferiorly down the spine

51

. IVDs in the lumbar spine are the largest with a height of

around 1 cm and a diameter of 4 cm

52

. For this reason, the lower back is the most

common area for disc degeneration, since diffusion of nutrients to the cells is much more
difficult and takes longer to occur.

2.3 Disc Degeneration
As we age, the disc degenerates. The incidence of low back pain increases with
age, creating a relationship between age related disc degeneration and the frequency of
low back pain 22,53. What is less understood are the mechanisms causing this degeneration
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and the process through which the degeneration occurs. Many researchers believe that
the degeneration of the spinal disc is a natural aging process. IVD degeneration involves
tissue loss or destruction over time, which decreases disc height and ultimately sacrifices
mechanical function of the vertebral body. However, evidence suggests other factors are
involved with increasing disc degeneration such as cell nutrition and transport, the
presence of degradative enzymes, mechanical loading, smoking, and exposure to intense
vibrations 54-56. Although many of these factors may contribute to the aging process, they
cannot be ignored, leading to the term degenerative disc disease (DDD) which
encompasses all of the degenerative effects of aging.
Presumably, it is difficult to characterize the morphology of the degenerated disc.
Many researchers have developed ways to grade disc degeneration, however, these
methods do not deal with the entire disc and do not completely characterize all the levels
of degeneration causing some ambiguity 57. Clinically, disc degeneration and disc height
are evaluated using magnetic resonance imaging (MRI). MRI enables each portion of the
IVD to be investigated and allows changes in the disc to be analyzed

58,59

. MRI is the

most clinically effective way to analyze disc degeneration by comparing disc water
content and height, and looking for tears or irregularities within the tissue 60. When the
disc loses height due to tears in the AF or the NP bursting, the compressed vertebrae may
pinch spinal nerves or rub together, causing intense pain. Some pain from the IVD is
thought to arise from nerve fiber growth into the degenerated disc 61.
Disc degeneration may be influenced by calcification with calcium phosphate
crystalline deposits, as the presence of these deposits increase as the disc ages, hindering
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nutrient diffusion

62

. Also, the amount and size of PGs within the NP significantly

decreases with as the disc degenerates

41,63-65

. Decreases in PG content are correlated

with dehydration as these molecules are major contributors to the higher water content in
the IVD
fibrous

22

. At early stages of disc degeneration, the NP dehydrates and becomes more

66-68

. Desiccation of the NP is followed by tearing within the AF (Figure 2.3).

These events may result in further disc matrix degradation, loss of hydration, and
subsequently a decrease in disc height. Each of these events decreases the discs ability to
properly function.

Figure 2. 3: Picture of normal disc (left) and degenerated disc (right) where the
degenerated disc is more disorganized and has a more fibrous appearance 69.
As disc degeneration progresses, there is a significant loss in PGs, water, and
collagen type II. Cellular microstructure may also be compromised during disc
degeneration. An alteration from a differentiated chondrocyte phenotype to a more
fibrotic phenotype in the NP occurs

70

. IVD shape and size are altered by changes in

water content which lead to a hindrance in the discs ability to absorb loads.
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Matrix turnover is common within the healthy IVD. During disc degeneration,
matrix is both degraded and altered through a variety of biochemical processes. PGs and
other ECM proteins are degraded by serine proteinases and matrix metalloproteinases
(MMPs), cytokines (specifically IL-1 & IL-6), nitric oxide (NO), and prostaglandin E2
(PGE2)

22,71,72

. MMPs are catabolic enzymes which encourage matrix degradation and

studies have shown degenerated discs to contain greater levels of MMPs. One goal to
stop disc degeneration is to create an environment in which the disc is in a more anabolic
state in order to increase matrix synthesis and decrease matrix degradation. A normal
healthy disc inhibits MMPs by using tissue inhibitors of MMPs (TIMPs). TIMP-1 can
increase the amount of PG and matrix production. MMPs 1,2,3,7,8 and 13 have all been
found in the IVD, with the majority of these proven to be more active in the degenerated
disc 73,74. MMP-1 (collagenase), MMP-2 (gelatinase), and MMP-3 (stromelysin) have all
been directly implicated in aggrecan and matrix protein degradation 75. MMPs 1-3 have
shown to degrade aggrecan, collagen types I and II, and collagen types IV and V,
respectively 22. Interleukin 1 (IL-1) and tumor necrosis factor α (TNF-α) may also affect
the disc metabolism. IL-1 may increase the rate of matrix degradation through the
release of MMPs and may also decrease PG production 76-78.
The collagens’ organized lamellar structure deteriorates, as well, and the degraded
matrix molecules become granular and evident within the NP 29,79. Throughout the aging
process, the presence of collagen remains the same 5. However, the different collagen
types and their ratios appear to change

80,81

. Collagen crosslinking is also altered during

degeneration, decreasing the ability of the disc to support mechanical loads
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82

. The

increase of disorganized collagen type I with the corresponding loss of collagen type II
and PGs in the disc matrix has been identified as a reason degenerated discs have inferior
mechanical properties 83.
Due to matrix degradation by enzymatic and structural changes, the disc and
matrix undergo mechanical changes as well. It has been observed that degenerated discs
have less height and are less stiff than normal discs 84. Structural changes are thought to
contribute to disc degeneration, in turn altering the ability of the disc to support
mechanical loading. During degeneration, the disc becomes less elastic, preventing its
ability to absorb and dissipate spinal forces

22,85

. As the IVD is loaded, it loses water

content. Studies have shown that excessive water movement caused by mechanical
loading decreases the synthesis of ECM 86. Biomechanical changes in the disc likely aid
in degeneration. IVD degeneration is identified by altered material properties, ECM, and
morphology

87,88

.

The lamellar morphology of the AF is highly disorganized in

degenerated discs, while overall disc structure is also modified. A degenerated disc has
distorted architecture, responding to stresses differently and possibly causing patients
perceived pain.
Cartilage does not maintain the inherent ability to regenerate. As the disc
degenerates and ages, there is a decrease in the number of viable cells 29,79. This decrease
along with a decrease in nutrient delivery have been implicated as important factors
causing disc degeneration

89

. It is not well understood, but a decrease in cell viability

may be due to apoptosis of the disc cells caused by mechanical loading of the AF.
However, many cellular factors must be considered when determining causes of disc
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degeneration. Degeneration of the IVD causes a significant structural alteration in both
regions of the disc, leading to a decrease in height, and ultimately resulting in pain.
During normal daily life, patients with degenerated discs experience excrutiating pain,
leading to a decline in their quality of life. The progression of disc degeneration leads to
further instability in adjacent vertebral levels 90.

2.4 Clinical Solutions to Disc Repair

2.4.1 Discectomy/ Fusion
Currently, it has proven difficult for clinicians to manage the low back pain
implicated by a degenerated IVD. The majority of patients are treated with rest, exercise
and/or medications 91. When these therapies are ineffective, surgery is required. The two
most common surgical procedures for patients with degenerated spinal discs are
discectomy and arthrodesis. Discectomy is a process in which the degenerated portion of
the IVD is excised or removed. Arthrodesis is a process of fusing two adjacent vertebral
bodies together and is often referred to as spinal fusion 92.
Although removal of degenerated or damaged disc tissue is common, it typically
leads to a loss in height of the IVD correlated with negative biomechanical changes and
anatomical problems. Some patients benefit from a discectomy as it may offer temporary
pain relief. However, postoperatively, the disc structure is highly compromised, leading
to further degeneration and instability

87

. After a discectomy, no regeneration of IVD

tissue takes place, making further disc degeneration likely 93.
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Due to the disadvantages and limited success of a discectomy, clinicians often
turn to spinal fusion to aid in patient comfort and further stabilize the spine. However,
the rates of clinical success for spinal fusion are also low 94. The main purpose of spinal
fusion is to prevent motion within the diseased spine segment. In turn, this loss in
mobility should decrease a patient’s perceived pain

95

. Problems with spinal fusion,

however, include possible degeneration of adjacent segments and failure to completely
immobilize the degenerated region of the spine

95

. Spinal fusion has proven to increase

stress concentrations on adjacent motion segments within the spine after analysis using
biomechanical studies and finite element analysis

96,97

. Because discectomy and spinal

fusion result in a loss of function and may promote adjacent disc degeneration, new
studies are being investigated to help alleviate a patients perceived back pain 98.

2.4.2 Replacement
Discectomy and spinal fusion are only short term solutions to recurring low back
pain or a degenerative IVD. A total IVD replacement, or arthroplasty, has advantages
over fusion, eliminating pain while increasing patient mobility 60,95. A primary advantage
of a disc replacement over spinal fusion is the preservation of some spinal motion

99

.

Implants for disc replacements should be biocompatible, durable, and easily implantable.
Disc replacements remove diseased tissue and reduce pain by restoring disc height. There
are different types of disc replacements including a NP replacement and total disc
replacements.
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NP replacements are less invasive and promote natural forces on the spine 100. NP
implants often have high water contents and promote fluid movement during loading to
enable nutrient delivery and mimic the native tissue environment. The prosthetic disc
nucleus (PDN) is a NP replacement consisting of a hydrogel core constrained by a
biodegradable woven fiber mesh to prevent excessive hydrogel swelling (Figure 2.4) 101.
The PDN has passed FDA guidelines pertaining to cytotoxicity tests and biomechanical
fatigue tests

102

. PDN is implanted in a dried form and absorbs fluid after implantation.

Currently, NP replacements must be implanted through incisions in the AF. This surgical
trauma, however, may compromise the integrity of the operated disc, resulting in an
inflammatory response that may ultimately promote the degenerative process. The use of
a NP replacement is not as widespread as the use of total disc replacement.
A total disc replacement is used when the integrity of the native AF has been
compromised or indicated as a cause of pain. Total artificial spinal discs also help reestablish flexibility of the spine. There are a few commercially available artificial spinal
discs that have been approved by the FDA. The SB Charitè® and ProDisc® are FDA
approved in the US with another, the Maverick®, undergoing clinical trials (Figure 2.4)
15,103-105

. The SB Charitè® and ProDisc® have both been used for more than a decade in

studies done mostly in Europe, and both disc replacements have shown a decrease in
operative time, blood loss, and length of hospitalization as compared with spinal fusion
106

. Patients implanted with the ProDisc® and the SB Charitè® reported significantly less

pain than spinal fusion patients, indicating that the recovery time may be shorter
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99,107

.

Other studies have confirmed the findings that artificial replacements have proven to
increase patient satisfaction compared with spinal fusion 108,109.
The SB Charitè® consists of 2 cobalt chromium alloy endplates and a biconvex
polyethylene (PE) spacer allowing for unlimited axial rotation, but only 20° flexion
100,110

. The endplates are coated with titanium and hydroxyapatite to promote

osteointegration into the adjacent vertebrae. On the other hand, the ProDisc® consists of
endplates composed of cobalt chrome molybdenum alloy with a fixed ultra-highmolecular-weight PE (UHMWPE) bearing surface that articulates on the metal

111

metal implants contain porous coatings or screws to promote bone ingrowth

100

. The

. The

Maverick® is an all metal disc implant containing a ball and socket that offers high
fatigue strength 112.

Figure 2. 4: Current Food and Drug Administration approved implants: PDN, SB
Charitè®, ProDisc® (left- right) 102,113,114.
The use and necessesity of total disc replacements is debatable and comparison
between different available implants is understudied. However, although there are
improvements to conventional treatments with artificial discs, there are also drawbacks.
Problems with current prosthetic devices include extrusion, infection, loosening, and
cytotoxicity

115-117

.

Long term survival and integrity of these implants is unknown
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because the devices are quite new in clinical use. Problems with a metal on metal
approach are a large compliance mismatch and the creation of toxic wear debris 100. This
microscopic wear debris can cause foreign body reaction in the body, and possibly
destruction of the tissue implant interface 100. As the implants are secured in the vertebral
bodies, the metal endplates may dislocate or migrate out of the bone. Loosening and wear
of the PE may occur in the SB Charitè® and ProDisc®, while the PE may also experience
creep, or even fracture 118-120. Because there are problems with current disc replacements,
and because they may fail, a revision may be required. Typically, revision operations
require a removal of the artificial disc followed by spinal fusion to immobilize the
affected tissue. Revision operations for artificial disc replacements are risky and
dangerous as scar tissue makes it difficult for the surgeon to navigate the large vessels
near the spine

121

. Therefore, longevity studies analyzing the long term effectiveness of

current implants are necessary.
Disc replacements allow some motion, but restrict certain movements and do not
replicate physiologic spinal motion or stability

118

. Total disc replacement procedures do

not provide an effective treatment method for all patients, as the results are not
consistently reproducible 95. Other problems involving current disc replacement strategies
include altered loading and compliance mismatch between the metal/polymer based
implants and the native tissue

122

. Often, current disc replacements do not absorb

compressive forces. During procedures for discectomy, spinal fusion, and disc
replacement, degeneration at other disc levels may be increased
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123

. Although implants

for disc replacement currently exist, no methodology has proven completely successful in
improving the ability of native disc tissue to regenerate.

2.5 IVD Regeneration
An apparent need for an alternative to conventional IVD replacement or spinal
fusion is obvious. Current artificial discs do not promote tissue remodeling. Tissue
engineering offers an attractive method to design a biomaterial that will aid in the
regeneration of natural IVD tissue. As current surgical procedures only focus on
symptoms related to IVD degeneration, IVD tissue engineering offers multiple strategies
to prevent and possibly cure degenerated discs by encouraging tissue repair. Tissue
engineering promotes tissue regeneration by encompassing the use of biomaterial
scaffolds, stem cells, and growth factors.
Therapeutic strategies for tissue engineering are advantageous because they can
be implanted simultaneously with a discectomy. Once removed, appropriate biomaterials
that have been designed to possess the desired biological, chemical, physical and
mechanical properties can then replace degenerated tissue. These biomaterial structures
should not illicit an immune response, have a structure similar to native tissue, be
biocompatible and biodegradable, and exhibit similar mechanical properties to those of
the natural tissue after successful regeneration. Many biomaterials currently exist which
have proven their biocompatibility, but newly developed materials must pass this
requirement first and foremost

124

. However, not all materials are suitable for every

application, and when choosing materials for the IVD many factors should be considered.
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An ideal scaffold would be porous to provide cell attachment and tissue ingrowth, while
also allowing the diffusion of nutrients and waste. The porous structure should allow
room for ECM to be secreted and ultimately form the tissue similar to normal native IVD
tissue.
Though biomaterial-free approaches do exist, in the spine, it may be necessary to
use biomaterials, as they serve as a load bearing structure to support biomechanical forces
while cells proliferate and create their own matrix. Biomaterials are important to provide
a stable environment for disc tissue regeneration

125

. Because the native disc has a low

density of cells, there is great concern that without a biomaterial carrier the implanted or
recruited therapeutic cells will have trouble synthesizing functional matrix to support
IVD biomechanics. Biomaterial carriers or scaffolds are important because biomaterials
offer cells a 3-D environment to guide cell behavior. Biomaterials can guide cell
attachment and growth along a defined micro and macrostructure to better mimic native
tissue structure. However, for tissue engineering purposes, it is important to note that
seeding cells at a high density is not attractive due to the unique IVD environment, which
is not conducive to maintain the viability of a large population of cells 11.
A biomaterial structure or therapy for disc regeneration should be able to handle
normal physiologic stresses on the IVD, which have been measured at around 1 MPa 47.
Biomaterial supporting structures should also be able to handle continuous dynamic
loading over time while proving fatigue resistant. Also, for tissue engineering, it is
important for the biomaterial to degrade over time and allow natural cell and ECM based
tissue to take its place. When designing biodegradable materials, it is important to control
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the degradation time and alter it in order to allow for new tissue infiltration. It is also
important to evaluate the degraded material and verify it to be non-toxic to prevent an
adverse immune response. Many materials offer the advantage of being able to have their
mechanical properties and degradation times specifically tailored by creating copolymers,
varying molecular weights, and altering crosslinking density. These materials include
both synthetic and natural biomaterials, with many of these polymers showing superb
biocompatible properties. Natural materials offer an advantage of promoting cell
attachment and cellular recognition of the material. However, it is much easier to tailor
the mechanical and physical properties of synthetic materials. Each of these material
types show promise for IVD tissue regeneration.
One major hurdle in the development of a scaffold for IVD tissue engineering is
the ability of researchers to mimic the lamellar organization of the AF 11. The native disc
histology and dynamics should be mimicked in biomaterial structures for IVD
regeneration. In this regard, the ability of a biomaterial structure to enable natural motion
may help prevent tissue degeneration at adjacent disc levels while encouraging natural
tissue regeneration.
Tissue engineering techniques are mainly evaluated on the ability to increase
ECM synthesis and restore disc height. When evaluating a biomaterial structure, cells in
the NP region should be more morphologically rounded as this morphology has proven to
synthesize more collagen type II, while cells in the AF region should be more elongated,
as this morphology has proven to synthesize more collagen type I

11

. The majority of

successes with tissue engineering approaches for IVD regeneration have focused on the
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production of ECM and PGs which increase water content and mechanical stability.
Qualitative studies such as staining with H&E, Alcian Blue, and Safranin-O are useful in
evaluating specific cell behavior and matrix synthesis on scaffolds.

2.5.1 Cell Based Therapy
A large focus in the field of IVD tissue engineering is currently supported by cell
based transplantation therapies. Mesenchymal stem cells (MSCs) are thought to halt IVD
degeneration and possibly regenerate some tissue despite the degree of degeneration

126

.

MSCs can be found in bone marrow, adipose tissue and many other connective tissues
and are a multipotent type of adult stem cell that are less susceptible to tumor formation
than embryonic stem cells

126,127

. Stem cells can be differentiated down a chondrogenic

pathway and may have the ability to express IVD cell phenotypes. Because MSCs lack
HLA class II antigen expression, they may have the ability to be used for allogenic
transplantations

128

. The delivery method of cell based therapies would be primarily

through injection into the IVD.
MSCs in hypoxic situations (2% O2) exhibit a tendency to differentiate towards a
phenotype similar to that of NP cells 4. Under hypoxic conditions MSCs increased the
amount of surface receptors for matrix and integrins, specifically β1, β3, and α2 integrins
while maintaining desired levels of CD44 (hyaluronan receptor), CD105, CD166
(ALCAM) 4. When injected into the degenerated disc tissues, stem cells may naturally
differentiate towards a chondrocyte phenotype based on the environmental cues. MSC
transplantation has shown to restore native disc height, cellularity, and structure in animal
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models (Figures 2.5 & 2.6)

123

. Transplantation of human chondrocytes has proved

effective in the therapeutic treatment of lesions within cartilage tissue

129

. However,

chondrocytes are difficult to obtain for cell culture due to their limited availability in the
adult human body.

Figure 2. 5: Normal rabbit IVD, sham operated disc, MSC transplanted disc(left-right)
123
.

31

Figure 2. 6: MSCs transplanted (arrow shows injection site) into the NP region at 2
weeks (a), and at 24 weeks (b) with circled region showing increased cell viability and
expansion at 24 weeks 123.
Autologous cells would likely be approved clinically as immune rejection would
not pose a threat. Recent success has been shown in this field as injected autologous cells
have reduced pain and maintained disc height

130

.

Autologous disc chondrocyte

transplantation (ADCT) is a procedure where patients’ own cells are transplanted into the
disc region 12 weeks after a discectomy

130

. A large scale, multicentered, randomized

clinical trial called EuroDisc evaluated the effectiveness of ADCT

130

. Two years after

ADCT, patients showed a decrease in pain, with a significant increase in PG and fluid
content as compared to patients who underwent discectomy alone

130

. The study was

considered a success as one of the primary goals for IVD tissue engineering is to
eliminate patient pain.
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Cell therapy and injection based methods may have limitations because cell
leakage could occur after injection 131. Also, injected cells must be able to remain viable
in vivo under high pressure and also must produce ECM to help increase disc height. This
may prove very difficult without the use of a biomaterial carrier for initial mechanical
support 132. Another disadvantage for biomaterial-free methods is the inability to support
in vivo biomechanical forces during tissue regeneration

125

. Autologous cell based

approaches are not efficient as they require multiple operations to retrieve the cells and
then implant the expanded cells back. The use of autologous cells also appears to be an
expensive and time costly procedure. Using allogenic transplantations may allow stem
cells to be expanded in vitro to create a steady supply of on demand cells for therapy.
Stem cell lines may also be readily accessible, but their future use clinically remains in
doubt due to a lack of understanding and possibility of tumor growth.

2.5.2 Signaling Molecule Based Therapy
Different signaling molecules are also being investigated as therapeutic strategies
for the treatment of disc degeneration. Molecular therapy offers a way to reduce disc
degeneration and possibly prevent or reverse the entire process of degeneration. If
signaling molecules were to be used alone, they would have to be injected into the
degenerated portion of the disc using a needle. Using multiple molecules to signal more
than one cell activity may be more effective than using a single signaling molecule 70, as
each of these molecules may play a specific role in allowing the IVD to regenerate

70

.

Table 2.2 summarizes signaling molecules, and whether they function as mitogens or
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chondrogenic morphogens. Certain signaling molecules can decrease the inflammatory
response and therefore protect the disc from further degeneration. Signaling molecule
therapy to regenerate the IVD may prove to be an especially important therapy in early
stages of disc degeneration, where disc structure has not yet been compromised.

Table 2. 2: Different categories of therapeutic molecules for the IVD.70
Category
Mitogens

Molecule
IGF-1, PDGF, EGF, FGF

Chondrogenic
Morphogens

TGF-β, BMP-2, BMP-7 (OP-1), BMP-13 (GDF-6, CDMP-2),
GDF-5 (CDMP-1)

Signaling molecules and their expression patterns in the normal IVD are essential
to understand the differentiation of IVD cells. Signaling molecules bind to specific
receptors, activating signaling responses to control cell behavior

133

. Signaling molecule

therapy explores the idea that different signaling molecules may work together to allow
tissue remodeling. In addition to the use of signaling molecules, matrix is continuously
synthesized and degraded in the IVD, which provides the opportunity to use enzymes and
inhibitors to increase matrix synthesis or slow degradation.
Signaling molecule therapy may be a viable strategy for promoting the restoration
of native disc matrix. Mitogens are molecules that help cells proliferate or increase the
rate of mitosis. It has been shown that mitogens, such as insulin-like growth factor-1
(IGF-1), epidermal growth factor (EGF), and fibroblast growth factor (FGF), increase the
rates of disc cell mitosis 70. It also demonstrated that some mitogens, such as IGF-1 and
PDGF, also upregulate PG synthesis 134. Further, some mitogens such as PDGF and IGF-

34

1 have proven to help preventing the apoptosis of AF cells

135,136

. Chondrogenic

morphogens can differentiate cells to express a chondrocytic phenotype instead of a
fibrotic phenotype. Transforming growth factor-β (TGF-β), bone morphogenic proteins
(BMPs), and growth and differentiation factors (GDFs) are molecules characterized as
chondrogenic morphogens. The synthesis of type II collagen, Sox9, aggrecan, and GAGs
is associated with chondrogenic morphogens as well 70. Of these molecules, TGF- β1 was
found to best maintain IVD chondrocyte viability

137

. Some chondrogenic morphogens,

such as TGF- β1, are able to increase disc cell proliferation and PG synthesis

138

, and in

the meantime to decrease the activity of MMP-2, which slows disc degeneration

138,139

.

Some chondrogenic morphogens, such as bone morphogenic protein (BMP-7), also called
osteogenic protein-1 (OP-1), can increase the synthesis of multiple disc matrix proteins,
such as PG, aggrecan, and type II collagen

140-142

significantly increased the production of PGs

. Figure 2.7 demonstrates that OP-1

142

. Because that, BMP-7 has the

therapeutic role to aid the regeneration of the NP after injection and increase disc height
143,144

. Interleukin-1 (IL-1) and MMPs have been found in degenerated discs, all of which

increase matrix degradation

60,71,72,75,145

. Therefore, activities of IL-1 and some MMPs

should be inhibited to stop disc degeneration

146,147

. BMP-7 inhibits the inflammatory

cytokine IL-1 and prevents the matrix degradation while increasing matrix synthesis 148.
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Figure 2. 7: PG content in the NP was significantly greater than the other IVD regions
when treated with BMP-7. All regions showed significant difference in PG content
when treated with BMP-7 when compared to controls 142.
Many different signaling molecules have been implicated in IVD regeneration.
BMP-2 provides evidence of a natural affinity to increase cellular differentiation towards
a chondrocytic phenotype because it increases the expression of aggrecan, a PG, and type
II collagen. BMP-13, also called GDF-6 or cartilage-derived morphogenetic protein-2
(CDMP-2), has also proven to increase PG synthesis, though less effective than BMP-2.
GDF-5, also called CDMP-1, which has been found in precartilaginous development of
long bone formation, has worked better than TGF- β1, IGF-1, and FGF in restoring disc
height in experiments. Similarly, FGF has shown to increase matrix production
throughout the disc

70,138,149

. Walsh et al. have also analyzed the efficacy of different

signaling molecules, including GDF-5, IGF-1, FGF, and TGF-β1, for IVD regeneration
150

. Cell population increased in the NP and inner AF in response to GDF-5 while the NP

of TGF-β1 treated discs also showed evidence of cell aggregates, suggesting that GDF-5
and TGF-β1 promote disc regeneration

150

. As many signaling molecule based studies
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have not provided concrete evidence, more thorough examination on the effects of each
biomolecule is needed.
Cell and biomolecule based therapies will likely only be successful at the
beginning stages of disc degeneration, before the disc composition and morphology have
changed dramatically

126

. Drawbacks to growth factor therapy are that the degenerated

portion of the disc cannot be removed and the disc height is not increased initially.
Another major downfall is the biomolecules’ short half-life

151

. If signaling biomolecule

based therapy is to be successful, it should be coupled with a biomaterial carrier in order
to avoid biomolecule denaturation. These biomolecule should have a temporal release
profile in order to control the release amount. The ideal biomaterial could release
desirable biomolecules into the IVD to promote successful tissue regeneration while also
increasing the disc height and mechanical stability. One example using biomaterial to
assist biomolecule based strategy is incorporating platelet-rich plasma (PRP) into gelatin
microspheres, which allows injection of the material into the NP 152. PRP contains many
signaling molecules that have been implicated to promote IVD tissue regeneration, while
improving PG synthesis in the IVD (Figure 2.8) 152,153. These gelatin microspheres served
as a delivery vehicle to enable the sustained release of growth factors from the PRP to
promote tissue regeneration as the gelatin degrades 152.
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Figure 2. 8: Optical density of PGs in the NP (A), and AF (B) showing that discs
treated with PRP loaded gelatin microspheres showed a much higher presence of PGs
in the NP and AF as compared to control groups and PRP-only groups 152.

2.5.3 Hydrogels
Biomaterials that crosslink and gel upon injection into the desired site may show
promise in the application of IVD regeneration. Injectable biomaterials are important
because they are less invasive than most conventional surgical techniques. Hydrogels,
which are in this class of injectable biomaterials, absorb large quantities of water and will
facilitate disc regeneration by acting as a temporary scaffold and increasing hydration
while aiding nutrient transport. They can also serve as a carrier or delivery vehicle for
cells and signaling molecules. These materials, however, may only aid in the regeneration
of the NP as the materials are physically and mechanically most similar to this portion of
the tissue. IVD cells in some hydrogels will take on a natural rounded morphology,
similar to that in the NP. Replacing the degenerated NP with hydrogels is an attractive
method for NP regeneration. As recently as 2005, the FDA has proposed the use of more
non-invasive therapeutic strategies to prevent disc degeneration, such as hydrogel
injection into the NP

154,155

. Most of the hydrogels currently under investigation are
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liquids at the time of injection, and undergo a gelation process after injection

123

. Many

hydrogel materials may be used for IVD tissue engineering.
Different hydrogel materials have been developed to mimic the NP of the natural
IVD

11

. Baer et al. used an alginate hydrogel to preserve the IVD cell phenotype. The

IVD cells seeded in alginate demonstrated enhanced production of PGs, collagen types I
& II, keratin sulfate, and chondroitin sulfate, all of which are constituents of the native
disc 27. However, the alginates anionic traits may prevent the formation of collagen into
its natural fibrillar structure. Chondrocytes cultured in agarose gel maintained a collagen
and PG structure comparable to that of natural cartilage 27.
Collagen hydrogels are attractive as they are constituents of native disc tissue. NP
replacement with collagen gels has proven to restore disc height with advantageous
mechanical properties in bovine animal models

156

. Also, collagen type I gels have

proven to promote IVD cell proliferation while also expressing both anabolic and
catabolic genes, signifying matrix synthesis and degradation, respectively

125

. These 3-D

gels were used to determine how cyclic strain and hydrostatic pressure affected cell
behavior

125

. Cyclic strain at a physiologic frequency of 1 Hz increased anabolic

expression of collagen type II and aggrecan while also decreasing catabolic expression of
MMP-3

125

. Hydrostatic pressure increased expression of collagen I and aggrecan while

it decreased expression of MMP-2&3

125

. Therefore, moderate mechanical loading may

aid in matrix synthesis while also decreasing matrix degradation
has already been used to regenerate cartilage clinically

157

125

. Collagen hydrogel

. Collagen gel promotes IVD

cell viability and the production of native matrix to prevent a significant loss in disc

39

height

158

. Furthermore, collagen hydrogels loaded with MSCs helped preserve the NP

and the structure of the AF in animal models, allowing for enhanced disc regeneration as
compared to collagen alone

123

. Some researchers are also investigating type II collagen

hydrogel for IVD regeneration. Type II collagen is the dominant collagen type in native
NP tissue and support NP cells very well. However, type II collagen degrades rapidly and
only last for 2-3 weeks, which is not sufficient time to allow functional matrix to be
synthesized to support physiologic loading

123,154

. Most current studies on collagen gel

are only focus on the regeneration of one region of IVD tissue

158

. A better strategy

would be using heterogeneous hydrogel for the regeneration of different regions of IVD
tissues.
Hyaluronan (HA) gel is another material often used in IVD regeneration because
it is a natural component of the native disc matrix, as well as because it increases the
water content within the scaffold to enhance the discs load bearing capacity

93,159,160

.

Injectable HA hydrogels have proven to prevent fibrotic tissue formation after removal of
the NP in pig animal models

161

. In one study, viscous HA hydrogels were used as

biomaterial carriers for the delivery of MSCs into rat coccygeal discs

91

. Four weeks

after injection, cell viability increased 91. However, after 4 weeks, the discs treated with
the MSC therapy did not show a significant difference from the sham operated animals 91.
This may be because sufficient matrix was not produced.
Chitosan hydrogel has been proposed to serve as a NP replacement

162

. Chitosan

is especially attractive for IVD regeneration as it has shown to promote chondrocyte
attachment and proliferation while having similar properties to extracellular matrix
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(ECM) in native cartilage

163-166

. Chitosan has the ability to self associate or form

covalent cross links, which enables a more complete hydrogel network. This type of
crosslinked hydrogel allows time for cells to manufacture ECM since polymer
degradation time is increased. Chitosan hydrogels can enhance the viability of
chondrocytes and aid in an increase of aggrecan synthesis 52. Cationic chitosan may be an
ideal biomaterial hydrogel to use as a replacement for the NP portion of the IVD because
it may aid in the attraction of anionic aggrecan molecules 52. This attraction would allow
for the possible accumulation of PGs and subsequently an increase tissue hydration. In
one particular study, lower molecular weight chitosan (2.5% Protasan UP G213)
exhibited superior cell viability compared to higher molecular weights

162

. Using 1% to

1.5% cationic chitosan hydrogels seeded with NP cells, roughly 80% of the synthesized
PG content was retained in the hydrogels 52.
Synthetic hydrogels can be manipulated to provide different mechanical
properties depending on their application. Some of the synthetic hydrogels used in IVD
regeneration include polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyvinyl
pyrrolidone (PVP), and polyethylene oxide (PEO)-polypropylene oxide (PPO). PEG
hydrogels have been used as biomaterial carriers to deliver MSCs into the NP in rat
spines while maintaining cell viability 167. PVA/PVP hydrogels have also been developed
to serve as minimally invasive, injectable NP replacements

168

. However, no evidence

was provided proving the ability of a PEG hydrogel to withstand loading or aid in matrix
retention while the PVA/PVP materials have not been proven to produce cell morphology
similar to the native NP 167,168. Pluronic F-127 , a PEO/PPO copolymer hydrogel allowed
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the synthesis of cartilage tissue, however, it cannot retain its initial shape and is
unsuitable for mechanical loading.169 Although few synthetic hydrogels are currently
investigated for NP applications within the IVD, many synthetic biomaterials are being
developed to mimic the AF structure which will be discussed later.
Currently, most studies on hydrogels for IVD applications are focusing on natural
based materials. Although synthetic materials and their properties are easier to control,
natural hydrogels provide a better environment to mimic the NP of a disc implant. One
issue with injectable hydrogels is their propensity to leak out of the injection site before
completely curing/gelling. Because hydrogels are mostly used to mimic the NP, other
biomaterial structures are investigated to better recreate the overall structure of the AF
and the native disc as a whole.

2.5.4 Biomaterial Scaffolding
A variety of solid biomaterial scaffolds have been investigated for IVD tissue
regeneration. Because fibrochondrocytes may require chemical and mechanical signals in
order to function and regenerate normal IVD tissue, scaffolding that has the ability to
support physiologic loading is desirable 170. Given the unique structures of IVD tissue at
different regions, it is important for scaffolding constructs to accurately address the
structure and composition characteristics of each region. More specifically, the NP and
AF structures need to be better mimicked to provide direction and guidance for cell
alignment and matrix deposition.
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Annulus Fibrosus Scaffolding
Many different polymeric biomaterials have been used in attempts to regenerate
the AF. PLA, PGA, and the copolymer PLGA appear attractive for tissue scaffolds
because suture products based on these materials have been approved by the FDA for
human use

171

. However, PLA and PGA alone are problematic for IVD applications

because they are hydrophobic and do not promote cell adhesion

172

. Therefore, they are

often combined with other materials to enhance cell responses. Examples of these types
of materials include small intestine submucosa (SIS), demineralized bone matrix (DBM),
and gelatin, which have been combined with PLGA to improve cell attachment and
growth

171,173

. Another downside to the use of PLA, PGA or its copolymers is that their

acidic degradation products elicit an inflammatory response 171.
SIS is an acellular material containing 80-90% oriented collagen fibers, GAGs,
and growth factors, including bFGF, VEGF, and TGF-β

174,175

. Biodegradable SIS

scaffolds improve PLGA materials for IVD applications as they allow incorporation of
growth factors to increase metabolic activity and matrix production of cells 176. Further,
positive gene expression proved that acellular SIS materials promoted ECM and GAG
production (Figure 2.9) while improving cell migration into the material after 1 month
176,177

. Also, SIS resorbs in 3 months, which is beneficial for IVD tissue regeneration as

it allows time for the synthesis of ECM while supporting biomechanical loadings.
However, a downside to SIS is that it has a rough and smooth side, and cells cannot
attach to the smooth side 178.
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Figure 2. 9: SIS cell seeded scaffolds show significant increase in GAG content in AF
(A), and NP (B), as compared to non seeded scaffolds in vitro. *p< 0.001, **p< 0.01.176
Studies investigating cell attachment for IVD scaffolds have proven the ability of
DBM and gelatin to promote cell attachment as compared to PLA alone (Figure 2.10) 173.
Materials similar to DBM, such as Bioglass®, were also incorporated into an IVD
scaffold. 3-D PLA foams composed of 0, 5, and 30 wt% Bioglass® particles were tested
to determine the constructs ability to satisfy the requirements for a tissue engineered IVD
179

. The 30% Bioglass®/PLA composites increased cell proliferation and exhibited

significantly higher GAG and collagen production as compared to PLA alone

179

. One

downside to the use of DBM and Bioglass® materials, though, are the materials
compliance and rigidity. This becomes an issue as the scaffold may not have the ability to
absorb loads in vivo. Also, these biomaterials may not be able to be easily implanted,
since they are not elastic enough to be press-fitted into the void disc space.

44

Figure 2. 10: Top: LIVE/DEAD imaging of cells on PLA (A), gelatin (B), and DBM
(C) scaffolding with diameters of 0.7-1.1 mm, 100-150 µm, and 1-2 mm, respectively.
Bottom: SEM after 1 month of culture showed that PLA was smooth (A), gelatin had
interconnected pores (B), while the DBM consisted of an oriented structure (C) 173.

Other degradable polyesters besides PLA and PGA, such as polycaprolactone
(PCL), have also been combined with DBM to increase cell attachment. A scaffold with
an outer DBM region and oriented layers of PCL in the inner region was used to recreate
the AF structure (Figure 2.11) 180. The use of DBM improved the compressive and tensile
strength of the scaffold 180. However, this scaffold only mimics the AF region, and does
not attempt to incorporate an integration within the scaffold for a NP region. Although
cells infiltrated the scaffold and produced matrix, they did not elongate and align in an
organized fashion like the native tissue (Figure 2.12)

180

. Also, as seen in previous

studies, the biomechanical properties of the scaffolding construct are not elastic and do
not match those of the native tissue.180
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Figure 2. 11: Safranin-O staining of normal rabbit IVD (a,b). PCL scaffold fabrication
technique showing concentric layers of scaffolding 180.

Figure 2. 12: Scaffolding at different magnifications using safranin-O staining (P:
PCL, C: Chondrocytes), and collagen type II fluorescent staining (right top:
cells/scaffold, right bottom: control scaffold) after 4 weeks culture 180.
PCL alone has also shown success in emulating the organized collagen fibers in
the native AF. For instance aligned PCL nanofibers have been bundled together in order
to create a single lamella with 1 mm thickness

181

. AF cells seeded onto these PCL

bundles oriented in alignment with the fibers and synthesized matrix

181

. Though this

scaffold provided accurate 3-D microstructure of a single lamellae, this technique needs
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to be improved by fabricating multiple lamellae within the same scaffold to accurately
mimic the native tissue architecture 181.
As can be seen, there have been many materials and structures that have been
investigated for AF tissue regeneration, yet there has been little evidence of how these
materials will integrate with the vertebrae. Takahata et al developed a 3-D polymer fabric
(3-DF), mimicking the shape of the IVD, which was composed of UHMWPE and coated
the top and bottom surfaces with hydroxyapatite bioceramic granules in hopes of
promoting vertebral body ingrowth. Animal studies using this 3-DF have demonstrated
bone growth into the construct, as well as firm fixation to the vertebral body

182

. 3-

DF/UHMWPE discs resisted fatigue and their mechanical properties remained constant
after 2 million cycles of dynamic loading, proving the materials durability

183

. One

problem with this scaffold design, though, is that it was too rigid and did not accurately
replicate a biphasic NP and AF region.

Nucleus Pulposus Scaffolding
As mentioned above, many materials have been extensively used for AF tissue
engineering applications. Some of these same materials have also been used as NP
scaffolding materials. For example, PLGA (70:30) scaffolds were used to regenerate the
NP tissue using a canine animal model 83. Evidence of tissue regeneration by chondrocyte
type cells and increased ECM was observed after scaffolds completely degraded at 4
weeks

83

. Similarly, a NP replacement composed of biocompatible and incompressible

polycarbonate urethane has shown to sustain biomechanical loading to maintain disc

47

height after a discectomy 184. The material consists of a memory coiling spiral which can
roll into shape after being implanted into the region of the removed NP (Figure 2.13) 184.
A drawback to the use of polycarbonate urethane is that the AF must be intact and
healthy to support spinal loads

184

. However, because these materials are not injectable,

they may damage the AF, which may lead to further disc degeneration. Therefore, a
material for NP regeneration combined with other scaffolding materials used in AF tissue
engineering is a more attractive idea to mimic the biphasic IVD composition.

Figure 2. 13: Human cadaveric IVD after NP removal (A), and after implantion of
memory coiling spiral in the NP (B) 184.
Biphasic IVD Scaffolding
It has been shown that a variety of materials have been used to emulate one region
of the IVD. However, these materials can be used in conjunction in order to create
composite structures that mimic the biphasic structure of the natural IVD and
simultaneously reproduce NP and AF tissue. Composites that use polymers such as PGA
or PLGA to mimic the AF, and alginate to mimic the NP have been developed 185,186. In
one design, a radically oriented PGA mesh combined with an alginate hydrogel has been
formed into a composite to emulate the AF and NP, respectively. Each of these materials
maintained their distinct regions after 4 months implantation (Figure 2.14) 185. Also, this
scaffold allowed for newly formed NP and AF tissue, which possessed a high intensity
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safranin-O staining after 12 weeks in vivo, proving the formation of cartilage tissue

186

.

Further, the GAG content and compressive modulus of the PGA-alginate scaffolds
increased to values similar to native mice IVD levels (Figure 2.15) 185. In another study,
PLGA and alginate scaffolds had similar morphology and composition, as well as the
structure of newly formed tissue, to that of the native tissue

186

. One limitation of these

particular scaffolds, however, is that the AF region of these materials was not as lamellar
and organized as the native tissue

186

. Another downside to the use of PLGA or PGA

with alginate is that the mechanical properties are not as similar to human IVD tissue,
which is necessary for IVD tissue engineering 185.

Figure 2. 14: Top: Both regions of the scaffold encouraged GAG synthesis similar to
native tissue in mice (left), while the modulus of the scaffolds also increased over time
to reach values similar to native tissue. Bottom: PLA/PGA and alginate scaffolding
before implantation (A), and implanted for 4 weeks (B), 8 weeks (C), and 16 weeks (D)
showing two distinct IVD regions.185
Like alginate, hyaluronan (HA) hydrogels have also been combined with PGA
scaffolds. Absorbable PGA scaffolds have been combined with fibrin-HA solutions,

49

containing expanded human IVD chondrocytes, and formed IVD-like tissue after 2 weeks
in culture

160

. In vitro, IVD cells assembled in 3-D on these scaffolds, while passing

necessary biocompatibility requirements and showing no decrease in cell viability as
observed by LIVE/DEAD staining (Figure 2.15)

160

. Also, collagens and GAGs were

produced in 3-D culture, on the PGA fibrin-HA materials, however, a more fibrous tissue
was formed, as collagen type I expression was greater than collagen type II expression
160

. This response was unwanted as collagen type II is more desired in a healthy disc

regeneration. To expand on the use of PGA and HA, certain groups have used cell free
nonwoven PGA-HA resorbable scaffolds and immersed them in serum containing growth
factors in order to attract cells and induce IVD regeneration in rabbit models 159,187. After
12 months of implantation, the animals with the scaffold treated discs exhibited extensive
infiltration of ECM proteins, such as PGs and collagen type II, allowing for an enhanced
disc height as compared to the controls. This study proved that long term success of
PGA-HA materials is possible as chondrogenesis was observed, with an increase in PG
and water content (Figure 2.16)

159,187

. Also, the ECM synthesized had a similar

composition to native tissue and were resorbed completely between 40 and 60 days with
a 50% loss of mechanical integrity after 7 days 159,187.
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Figure 2. 15: LIVE/DEAD staining of the cells within the PGA fibrin-HA scaffold at 1
(A) and 2 (B) weeks. It can be seen in B, that live cells migrated into a more 3-D
pattern. The red seen in part B is a staining of the PGA fibers 160.

Figure 2. 16: H&E (A,C), and Safranin-O (B,D) staining 12 months after a discectomy
(A,B) or PGA-HA treated materials(C,D) showing increased cellular infiltration
(circles) in the implant treated discs and tissue necrosis (arrows) in the controls 187.
It has been shown that HA may be an effective hydrogel for IVD regeneration
when combined with appropriate scaffolds. For this reason, biphasic biodegradable PLA
nanofiber scaffolds consisting of an HA center have been tested
nanofibers resemble the native lamellar structure of the AF

103

103

. The electrospun

. During culture, cells in

the PLA-HA construct elongated and aligned in a concentric fashion on the nanofibers
while also increasing secretion of GAGs and other ECM content, as evidenced by H&E
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and alcian blue staining (Figure 2.17)

103

. PG staining with alcian blue showed no

distinct organization within the NP while the AF has a more organized structure,
mimicking native IVD tissue architecture (Figure 2.17)

103

. One issue with the scaffold,

though, is that it does not support necessary biomechanical loads

103

. The PLA fibers

should also be more aligned in the periphery of the construct to better mimic native disc
tissue.

Figure 2. 17: Left: Staining of PLA/HA scaffold showing increase in cellularity and
PG content in both the AF and NP over 28 days. Right: Quantitative assay showing
increase in GAG synthesis over time 103.
Natural polymers, such as collagen type I have also been used in conjunction with
hydrogels in order to create a biphasic IVD scaffold. In one study, a HA hydrogel
surrounded by collagen type I, at a ratio of 9:1, was used to make a composite scaffolding
material, which promoted growth and attachment of functional IVD cells for 60 days in
culture

137

. PGs including aggrecan, decorin, biglycan, fibromodulin, and lumican as

well as collagen types I & II all accumulated on the scaffold, showing that cells were
synthesizing matrix similar to that of the native IVD

137

. The synthesized biomolecules,

however, were not consistently retained within the scaffolds and often escaped into the
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culture media 137. For this reason, this particular biphasic construct is not effective, as the
materials should retain and organize matrix molecules into functional ECM in order to
properly function as an IVD scaffold.
As evidenced by previous studies, mechanical properties of IVD scaffolds are far
from satisfactory. Suitable mechanical properties can be achieved, however, with the
proper design and materials. One group, Gloria et al, created a scaffold with mechanical
properties that were very similar to those of the natural IVD122. The scaffold consisted of
poly (2-hydroxyethyl methacrylate)/ poly (methyl methacrylate) (PHEMA/PMMA)
(80/20 w/w) hydrogel combined with poly (ethylene terephthalate) (PET) fibers

122

. The

scaffolds showed a J-shaped stress-strain curve similar to most soft tissue, and did not
experience signs of fatigue under dynamic loading

122

. Furthermore, acrylate materials

can maintain a desirable water content of about 75wt% which is comparable to natural
IVD water content

188

. Although the PHEMA/PMMA/PET construct showed superior

mechanical properties as compared to other biomaterial structures, and is assumed to be
biocompatible, no data was provided to prove the scaffolds ability to support cell growth
and direct matrix synthesis

122

. Further evidence may show that this material construct

might be ideal for IVD regeneration.

2.6 Animal Modeling
In order to evaluate the effectiveness of the strategies developed for IVD tissue
repair and regeneration, it is important to use appropriate animal models. Also, because
the complete process of disc degeneration is not well understood in humans, animal
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models have become increasingly important. Animal models can help determine cause
and effect relationships of different factors that may relate to disc degeneration. For the
purpose of creating a degenerated disc, induced injury can imitate a degenerated disc 84.
Different methods have been used to simulate IVD degeneration with most models using
spines and tails 84. Results from animal studies have suggested that abnormal mechanical
loading conditions lead to symptoms of a degenerated disc. Using induced degeneration
in animal models, therapeutic strategies for IVD regeneration can then be evaluated for
success. If successful in smaller animals, tissue engineered strategies can be further tested
in larger animals that better mimic nutritional, biomechanical, and surgical applications
in humans 189.
Rodent models are necessary to establish the initial success of an IVD treatment
strategy. Rodent models help determine whether or not a specific regenerative therapy is
promoting a desired cellular response. In order to evaluate treatment, degeneration must
be induced. Research has proven that compressive forces can induce degeneration using
in vivo mouse tail models
puncture the IVD

189

190

. Degeneration can also be produced by using a needle to

. After induced degeneration, rat models have been used to test

regenerative based growth factor therapy by evaluating changes in PG content and
changes in disc morphology.
Small animal models, such as rabbits, are used when strategies have proven
successful in rodent models. Kroeber et al used axial mechanical loading on an in vivo
rabbit model to produce a degenerated disc (Figure 2.18)

26

. This method is the first

method where disc degeneration was induced and then treatment methods were evaluated
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in vivo 26. Rabbits spines that were mechanically loaded for 14 and 28 days exhibited a
significant decrease in disc height, as well as an outer AF structure that became
disorganized, proving that compression simulated IVD degeneration. PGA implants were
then tested in the animals with degenerated discs

26

. Abbushi et al were the first to

remove the degenerated disc, using open surgery microdiscectomy, on rabbit animal
models to test their implanted materials

159

. This method is advantageous over other

techniques as it is a more destructive resection of tissue, better simulating the clinical
environment 159.

Figure 2. 18: Rabbit animal model of IVD after dynamic compressive loading for 28
days showed significantly less height (B) than normal (A) 26
One inherent problem with modeling human IVDs is their size compared to
animal models. Human IVDs are much larger than most rodents and smaller animals, and
therefore transport of nutrients and wastes is much more difficult in human IVD 84. For
this reason, more expensive, larger animal models (canines, sheep, porcine, goats) are
necessary for in vivo studies as diffusion of nutrients to cells in these larger models more
accurately mimics human IVD circumstances. Canine spines under large compressive
loads have been used to model disc degeneration
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191

. Degeneration in sheep and goat

animal models has also shown to be advantageous for potential therapeutic strategies as
their IVDs are similar in size to humans, and their tissue does not naturally repair 192,193.
Researchers have also investigated porcine models by promoting degeneration and then
evaluating the effectiveness of a hydrogel containing stem cells to promote viability and
differentiation towards a chondrogenic phenotype 194.
Animal modeling in its later stages needs to be geared more towards better
mimicking a human spine size and biomechanics. The spines and IVD structures of
primates is highly similar to humans

126

. Also, because primates are bipedal, the forces

acting on their spines better mimic human loading conditions 126. Although primates may
be essential for studying IVD regeneration strategies in the future, to date most
researchers have not used primates as models because of ethical issues and high costs.189

2.7 Mechanical Properties
Since animal studies have shown that compressive forces can induce
degeneration, it seems there may be a correlation and a limit to the loads the IVD can
support before experiencing degeneration. The ECM of the IVD consistently bears loads
in the body, and these loads can be assumed to be primarily compressive 195. The IVD is
a viscoelastic tissue having time dependent responses to loading and experiences
nonlinear, anisotropic behavior 84,181. Therefore, static and dynamic compressive tests can
be used as preliminary indicators for the behavior of devices and biomaterial structures
for potential spinal disc applications.
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Disc cells are influenced by a variety of mechanical factors such as mechanical
stress, and osmotic pressure

27

. Mechanical influences that affect disc cell behavior

include static compression, hydrostatic pressure, and tensile stretch. Each of these
external stimuli changes the assembly of PGs, and collagen within the IVD. Atypical
loading on a healthy disc can cause cellular alterations within the disc, which may be
characteristic of a disease state

51

. Though some evidence suggests that normal

compressive spinal loads may encourage PG synthesis, loading may also alter the matrix
composition by decreasing the matrix production and degradation, and decreasing cell
activity

51

. Extensive mechanical loads may cause cell death, decreasing the amount of

cells available to synthesize and turnover stable ECM molecules

196

. During extended or

abnormal loading periods, the IVD may attempt to remodel to better support the loading,
usually resulting in a degenerated disc 190.
Because mechanical loading can be both implicated and compromised in a
degenerated IVD, it is important for biomaterial structure to have similar mechanical
properties compared to healthy, native tissue. Mechanical integrity, especially under
compressive stresses, is important for IVD implants and tissue engineered IVD tissues.
The compressive modulus of the IVD varies in each region. In the AF, the compressive
modulus has been reported to range from 0.116-2.3 MPa, while in the NP the
compressive modulus has been reported to range from 0.003-0.31 MPa. Therefore, a
tissue engineered construct should be able to withstand these loads with some safety
factor involved. It has been stated that the Young’s compressive modulus of IVD
scaffolds should range from 0.5-5 MPa and the ultimate strength should be at least 8-10
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MPa

11,38,197,198

. The NP and inner AF are deformed less during compression. Because

each of the IVD regions contains different matrix molecules, the disc has varied
mechanical properties in each region. In this regard, IVD implants and tissue engineered
IVD tissues should have distinct mechanical properties in each region. Mechanical
properties of IVD constructs need to be better characterized as the mechanical properties
are important for the IVD functions. Dynamic and static compression tests are
recommended for IVD constructs as the forces on the spine are primarily compressive 131.
However, for IVD regeneration using biomaterials, biomaterial structures should be able
to temporarily support limited amount of spinal loads while promoting matrix synthesis,
as the regenerating matrix will eventually bear the full spinal loads when the implanted
biomaterial structure degrades.

2.8 Conclusion
Worldwide healthcare goals involve the restoration and maintenance of native
IVD tissue to decrease its economic burden and impact. The degenerated spinal disc is
one of the most expensive medical problems currently encountered today as it causes
disability among many people in the aging population 130. One major hurdle in creating a
regenerative therapy for the IVD is that its structure is highly unique and has multiple
distinct regions. The NP is a disorganized conglomeration of collagen type II and highly
anionic PGs which help attract water to maintain the disc height. On the other hand, the
AF consists of highly organized collagen type I based lamellar architecture which helps
prevent bulging in the NP. The distinct structure of each region of the IVD enables the
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disc to withstand the everyday dynamic forces placed on the spine. Both the AF and NP
structures are avascular, meaning cellular nutrition is based solely on diffusion, and also
making repair of the tissue difficult, inevitably resulting in age related disc degeneration.
It is important to understand disc degeneration prior to determining an effective
therapy, since a researcher must know which factors are causing the degeneration in order
to stop it. All of the exact causes of disc degeneration have not been identified, although a
variety of factors have been implicated, including loss of biomechanical stability, poor
nutrition, genetic factors, and an increase in degradative enzymes. Disc degeneration is
accompanied by a decrease in viable chondrocytes and a loss in PG content within the
matrix followed by dehydration. During IVD degeneration, the disc structure of the NP
and AF are highly compromised leading to a fibrous and disorganized structure. As disc
degeneration progresses, the discs ability to support biomechanical forces on the spine
become compromised. Eventually, the disc becomes unstable, causing an extensive
perceived pain by the patient.
Clinically, the only solutions to a patient’s pain resulting from a degenerated disc
are therapy, rest, and medication. If these treatments are unsuccessful, a patient may
require the removal of the degenerated portion of the disc, spinal fusion, or an IVD
implant. Removal of the degenerated tissue does nothing to stabilize the spine and causes
problems relating to the decrease in disc height which leads to increased disc
degeneration. A current solution to a disc removal is spinal fusion which stabilizes and
restricts motion.

However, fusion creates its own problems as it increases stress

concentrations on adjacent discs, causing further degeneration. Therefore, the
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replacement of degenerated or damaged IVD tissue with a permanent implant is an
attractive alternative to spinal fusion. Current implants help restore patient mobility and
disc height. However, these implants have their own faults. Current NP replacements
damage the native AF upon implantation, causing an inflammatory response that will
eventually promote further tissue degeneration.

Total disc replacements also have

problems in that they form wear debris and have a large compliance mismatch, leading to
stress shielding on adjacent vertebral levels.

Another disadvantage to current disc

replacements is that they do not replicate physiological motion or promote natural tissue
repair.
To improve upon current solutions, tissue engineered IVD structures are being
developed to regenerate the native tissue. The necessity for the development of
approaches to promote IVD repair and regeneration is evident in the fact that problems
still exist with current therapies to disc degeneration. Researchers are currently
investigating different therapeutic methods to promote IVD regeneration, including cell
based therapies, signaling molecule based therapies, and biomaterial-based regenerative
therapies. Cell and molecule therapies alone are unlikely to be effective as they will not
be able to support in vivo spinal loads. Current NP hydrogel regeneration strategies are
unlikely to be successful as they may damage the AF. Once the AF is compromised,
some type of scaffold support structure will be necessary to support loads. Therefore, a
biphasic structure mimicking both the AF and NP is more likely to have a long term
impact in IVD tissue regeneration due to the inherent mechanical stability they would
provide. These tissue engineered IVD structures should have a similar structure and
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mechanical properties to that of the native tissue in order to properly integrate with the
tissue and resist failure. Scaffolds also have the ability to be coupled with bioactive
molecules in order to promote tissue regeneration or prevent an inflammatory response,
while allowing for mechanical stability 133,199,200.
Tissue engineering is the future for the treatment of IVD degeneration.
Conventional treatments for IVD degeneration do not meet the requirements to restore
patient satisfaction. Due to the failures of current therapies and techniques to prevent and
treat IVD degeneration, new methods are needed. Novel ideas are necessary to propel
IVD tissue engineering forward, starting with a basic understanding of design criteria.
Using previous successes and failures in tissue engineering, the regeneration of the IVD
is an achievable goal.
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CHAPTER 3
3. FABRICATION OF A BIOMIMETIC ELASTIC INTERVERTEBRAL DISC
SCAFFOLD USING ADDITIVE MANUFACTURING

3.1 Introduction
Over 80% of the adult population is affected by low back pain at some point in
their lives. Surgical procedures are performed on roughly 5% of the population to
alleviate this pain, amounting to nearly $90 billion in annual healthcare costs 1.
Degeneration of the intervertebral disc (IVD) causes compression of the spinal nerves
and adjacent vertebrae, proving to be a primary cause of low back pain. The exact causes
of IVD degeneration are unknown, but it is thought that natural aging, excessive
mechanical compression, and biological or genetic factors each play a significant role in
the degenerative process

2-5

. Current methods to alleviate the pain caused by a

degenerated disc include spinal fusion and artificial disc replacement. Spinal fusion does
not restore disc function and may cause further degeneration of adjacent IVDs by altering
the biomechanics of the spine 6. Artificial IVD replacements have recently started to
gather interest, with two IVD implants currently approved for use in the United States 7,8.
These implants help replace the degenerated disc and restore some motion; however, they
cannot sustain compressive forces due to their lack of elasticity. Additionally, current
implants may produce wear debris and cause stress shielding on the vertebrae, resulting
in further disc degeneration and eventually implant failure 9. Tissue engineered IVD
scaffolds may offer advantages over current approaches, including preservation of disc
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height and natural motion while encouraging formation of natural tissue. Additionally, an
artificially engineered elastic polymeric disc offers a solution to the problems
encountered with current disc replacements as it would be capable of supporting
compressive forces on the spine without permanent deformation.
Many researchers have attempted to fabricate an IVD scaffold, but none have
completely satisfied critical requirements for both reproducing morphological and
mechanical properties of native IVD tissue

10-12

. However, creating a tissue engineered

IVD has proven difficult, as its structure is highly unique, containing a highly aligned and
lamellar annulus fibrosus (AF). Overall, the IVD is avascular with a bean shaped
structure

13

. The AF is a collagen-rich fibrous structure containing between 15-25

multilayered, oriented concentric layers (lamellae)

14

. This lamellar architecture helps

support the biomechanics of the disc by preventing excessive tensile force from bursting
the inner IVD while supporting compressive forces on the spine 15. Cells within the AF
are highly oriented and parallel to the lamellar collagen fibers 16. To our best knowledge,
no researchers have replicated the microstructure of the AF when designing a tissue
engineered construct. Because it is vital that a tissue engineered structure closely mimics
the native morphology of the disc, a scaffold with a similar structure to the native AF,
containing concentric lamellar layers, would prove to be a significant advancement
compared to current tissue engineering strategies. Furthermore, the development of an
IVD scaffold with mechanical properties similar to those of native tissue are rarely
investigated. Therefore, a tissue engineered IVD construct that better emulates
mechanical properties of the native disc will prove advantageous in the future.
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A lamellar disc scaffold formed from elastomeric polymers would offer a high
compliance and allow restoration of natural three-dimensional spinal motions. A lamellar
construct mimics the natural histological structure found in the outer region of natural
IVDs and allows a greater surface area for cell adhesion, alignment, and growth.
Currently, many different techniques have been used to create an IVD scaffold

12,17-20

.

However, none have been able to fabricate a lamellar structure mimicking the natural
IVD histology. To this end, we created an additive manufacturing technique that
combines ultra-fine pipettes for liquid polymer extrusion and a freezing stage for the
solidification of the scaffolds. This scaffold fabrication method permits the use of many
different polymers and is suitable for creating scaffolds with different three-dimensional
configurations. This paper will primarily focus on the use of a biodegradable and elastic
polyurethane (PU) for the application of IVD tissue regeneration, as polyurethane
exhibits elastic properties similar to natural IVD tissue, and has shown to encourage
cartilage growth in previous studies 21.

3.2 Materials and Methods

3.2.1 Scaffold Fabrication
A custom-built computer aided manufacturing device integrated with a freezing
stage was used for this study as shown in figure 3.1. Microsoft Visual Basic was used to
program the device for three-dimensional scaffold designs. Scaffolds were designed by
manually programming the device to resemble the native IVD tissue structure as seen in
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the literature

22

. The nozzle tip was made from a calibrated fire-pulled glass injection

pipette to allow high resolution printing. Specifically, 5 µL glass capillary tubes
(Drummond wiretrol, Drummond Scientific Company, Broomall, PA) were heated and
pulled on a micropipette puller (Narishige PC-10, Japan) to have a well-controlled inner
diameter varying between 5 µm and 50 µm.
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Syringe Pump with Polymer Solution

A

Computer/
3D Scaffold Design
0.004 ml

Glass
Micropipette
Freezing Stage
H2O out
H2O in

Motors
z

Bioprinter
x

0.0 °C

Temperature
Controller

y

B

Figure 3. 1: Schematic (A) and image (B) of the apparatus using CAD, a temperature
controlled freezing stage, and micropipettes. The device allowed for control of the X-YZ axes down to micron level resolution, while separately controlling the polymer
solution extrusion rate.
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Degradable lysine diisocyanate (LDI, Kyowa Hakko Kogyo Co., Japan) and
polycaprolactone diol (PCL, Sigma-Aldrich, USA) based polyurethane was synthesized
and purified similar to techniques used by others

23,24

. Briefly, 1:1 molar ratios of hard

segment LDI and soft segment PCL were added dropwise into dimethylformamide
(DMF, Sigma) and stirred for 3 hours. The resulting polyurethane was then dissolved
again in DMF at a concentration of 15% w/v under nitrogen gas flow protection and
stirred overnight. This polymer solution was extruded out of a syringe through an ultrafine glass injection pipette. Polymer solution was fed at a flow rate of 0.005 ml/min onto
a glass collection plate placed on the freezing stage (maintained at -4° C). The
micropipette tip was positioned approximately 30 µm above the collecting substrate. The
freezing stage maintained the scaffold resolution by increasing the polymer solution
viscosity below its freezing point and causing the polymer to harden in place as it was
extruded out of the pipette tip. Briefly, the scaffold material is solidified through
temperature convection from the cold stage to the point where the material is extruded
out of the pipette tip. When the temperature is finely controlled, the polymer solution
will solidify upon extrusion after reaching its freezing point and allow the structure to
support subsequent layer by layer deposition. Thus, the device and freezing stage can
precisely control the extrusion and resolution of the polymer, therefore allowing the
creation of custom designed scaffolds. The approximate build time for each IVD scaffold
layer was approximately 3 minutes. After the printing of each layer, the micropipette was
raised 20-40 µm in the z-direction and the computer program continued to build the next
layer of the structure. After the printing procedure was done, solidified scaffolds were
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removed from the freezing stage and freeze-dried for 24 hours to extract the solvent.
Large ice crystal formation on the freezing stage was avoided, by operating in a low
humidity environment, because it alters the physical properties of the extruded polymer,
thereby affecting polymer shape.

3.2.2 Mechanical Properties of Scaffolds
Mechanical testing was used to characterize the compressive properties of the
scaffolds using unconfined compression experiments. Scaffolds (5.75 mm in diameter ×
2 mm in height) were compressed at a rate of 1 mm · min-1 using a DMA Q800 system
(TA Instruments, Delaware, U.S.A.) and stopped at roughly 50% strain (n=4).
Engineering stress and strain were recorded and evaluated. The compressive tests were
performed on hydrated samples at room temperature. Dynamic compression tests were
completed on the hydrated samples at room temperature at 0.008 Hz up to a compressive
strain of 65%. Tests were not completed past 65% compressive strain, as previous studies
have shown that the IVD only experiences roughly 15% compressive strain, and
compressive testing to 65% ensured the scaffold would perform well under extreme
conditions

25

. Dynamic shear testing was also performed on the scaffolds similarly to

previous studies on the IVD 26. Dynamic shear properties were measured for 12 samples
each at 3 compressive strains (15%, 30%, and 45%) using an AR G2 dynamic rheometer
(TA Instruments). Briefly, each sample was subjected to a shear strain of 1.5% at
oscillation frequencies ranging from 0.05 Hz to 1.05 Hz in 0.05 Hz intervals, similar to
previous dynamic testing conditions on IVDs
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27

. These frequencies were chosen as they

are comparable to normal physiologic loading rates in the IVD

28

. Dynamic shear

properties were measured at 3 levels of compressive strain because the disc is always
under some degree of compressive force, usually around 15%. Other levels of
compressive strains, e.g., 30% and 45%, were also tested to account for severe loading
circumstances.

3.2.3 In vitro cell culture experiments
Scaffolds used for cell culture were sterilized with 70% ethanol for 30 minutes and
then rinsed 3 times with sterile PBS for 2 hours per rinse. Bovine IVD cells were seeded
on the scaffolds at a density of 1x105 cells. RPMI 1640 Media with 10% FBS and 1%
antibiotic/antimycotic solution was changed every other day throughout the study. Cells
were cultured on the scaffolds for up to 19 days. An alamarBlue® assay to measure cell
proliferation and viability (Invitrogen, Carlsbad, CA) was performed on every other day
from day 1 to day 19 to examine the growth and cytocompatibility of IVD cells on
printed elastic PU scaffolds versus a flat surface control. Briefly, cells were cultured in an
alamarBlue® and media mixture at a ratio of 1:40, for 4 hours, after which the media was
removed and absorbance at 570 nm and 600 nm was measured using spectrophotometry.

3.2.4 Morphological Study
Scanning electron microscopy (SEM, Hitachi TM-1000) was used to visualize the
morphology of the printed scaffold. All fluorescent and light microscope images were
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taken using a Leica TCS SP5 AOBS Confocal Microscope (Leica Microsystems Inc.,
Exton, PA, U.S.A.). For fluorescent staining, cells were fixed with 4% paraformaldehyde
after 3 weeks of culture, and phalloidin 488 and DAPI were used to stain the actin
filaments and the nuclei of the chondrocytes within the scaffolds, respectively. The
morphology of the IVD cells was observed to determine if cells were spread out and
attached to the 3-D scaffolds.

3.2.5 Statistical Analysis
One-way ANOVA was performed on the values of G’(storage shear modulus) and
G* (complex shear modulus) across the frequency range 0.05-1.05 Hz with a least
significant difference (LSD) post hoc comparison set at p<0.05 using SPSS 17 statistical
software (Chicago, USA). The results of the alamarBlue® assay comparing PU scaffolds
with control samples were also analyzed using the methods described above.

3.3 Results

3.3.1 Scaffold Fabrication
The method presented in this paper uses a freezing stage coupled with a custom-built
additive manufacturing apparatus allowing for the creation of scaffolds with multiple
layers and lamellar structures using solid freeform fabrication through the extrusion of
polymer solutions onto a temperature controlled stage. The freezing stage aided in the
solidification of the structure at the time polymer solution was extruded out of the ultra-
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fine pipettes through convection of the cold temperatures from the stage to the extruded
polymer solution. Ultra-fine pipettes allowed for fabrication of scaffolds with similar
structure to native IVD tissue with the high resolution and reproducibility necessary for
controlling the scaffold microstructure. Figure 3.2 shows SEM images of the scaffold,
confirms the 3-D structure, and the ability of the scaffold to mimic native lamellar IVD
structure.

A

B

Figure 3. 2: SEM images of a custom designed and layered PU 3-D scaffold structure
mimicking the natural shape of the IVD and showing a lamellar structure (A), multiple
layers of PU stacked in a 3-D structure, proving accuracy and effectiveness of the
bioprinter, micropipettes, and freezing stage to maintain high resolution in three
dimensions (B).

3.3.2 Mechanical Properties of Scaffolds
Elastic properties were determined with mechanical analysis of the scaffolds in
compression and shear. The average compressive stress-strain curve is shown in figure
3.3A. The scaffolds showed a J-shaped stress-strain curve, observed in soft tissues similar
to the IVD. The initial compressive storage modulus (E’) in the toe region was 45.4 ± 5.6
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KPa (mean ± the standard error of the mean), while the compressive modulus (E’) of the
linear region was 350 ± 19.6 KPa. These values correspond to similar tests carried out on
native IVD tissue

28,29

. The shape of the curve indicates that the scaffolds significantly

stiffen under large strains (greater than 40%). Elastic hysteresis was observed in the
scaffold during dynamic compression (figure 3.3B). Scaffolds did not show permanent
deformation after 5 cycles of compressive loading up to 65% strain, which is significantly
more strain than native IVD tissue typically undergoes during loading, proving the
scaffolds can handle deformation well

25

. Aside from basic compressive testing,

compressive shear testing to 1.5% strain was also carried out as the native IVD undergoes
shear deformations

26

. During compressive shear tests, compression at 15%, 30%, and

45% strain were used, as compressive strains of around 15% are similar to normal
physiologic compressive strains

25,30

. The storage shear modulus (G’) represents the

elastic stored energy of the scaffold material. The dynamic shear modulus (G*) is
comprised of both G’ and G” (energy lost as heat) and can provide important information
as a material property.

The printed PU IVD scaffolds displayed significant elastic

responses, during shear tests, in which G* was primarily governed by G’. One-way
ANOVA was performed across each frequency for G*, G’, and G’’ with compressive
strain serving as the comparison factor. All of the dynamic shear properties were
dependent both on the frequency and the compressive strain. Increases in compressive
strain resulted in increases for G*, G’, and G’’. Increasing the frequency also increased
the compressive dynamic shear properties, but this was not found to be significant. The
compressive strain effect was found to be significant for G*, G’, and G’’ (p<0.05) as
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shown in Table 3.1. Since the material displayed primarily elastic behavior, the trends for
G’’ are not shown in figure 3.4 due to the minor contributions to G*. During shear
testing, all recorded frequencies between 0.05-1.05 Hz were analyzed against the
compressive strains and showed significant differences between all strains with p-values
all below 0.02. At a frequency of 1.0 Hz, compressive dynamic shear moduli were 57 ±
23.7 KPa, 97 ± 15.2 KPa, and 135± 12.6 KPa for 15%, 30%, and 45% compressive
strains, respectively. At a frequency of 1.0 Hz, compressive storage shear moduli were
56.7 ± 23.7 KPa, 96.5 ± 15.2 KPa, and 134± 12.4 KPa at 15%, 30%, and 45%
compressive strains, respectively. Figure 3.4 validates that energy is primarily stored by
the material during deformation, as G’ and G* are highly similar, proving the material
has significant elastic behavior. Furthermore, our results were very similar to other
compressive shear studies performed on native tissue 26.
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Figure 3. 3: (A) Stress-strain curve showing average behavior of printed PU IVD
scaffolds. Scaffolds exhibited elastic behavior, showing a J-shaped stress-strain curve
typically observed in soft tissues like the IVD. (B) Representative dynamic compressive
testing on PU IVD scaffolds which exhibited elastic hysteresis, and did not show
permanent deformation after multiple cycles of dynamic compressive loading.
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Table 3. 1: Statistical analysis for Dynamic Shear Moduli at 1 Hz between Compressive
Strains of 15%, 30%, and 45% (n=12).
Variation

Mean (KPa)

The standard
error of the mean

Significance

(KPa)
Storage

15%

56.65

23.74

Modulus

30%

96.5

15.16

(G’)

45%

133.9

12.55

Loss

15%

6.51

1.97

Modulus

30%

9.55

1.27

(G’’)

45%

13.09

1.63

Dynamic

15%

57.03

23.77

Modulus

30%

96.96

15.2

(G*)

45%

134.55

12.62

A

p<0.05

B
120

120
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p<0.05
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Figure 3. 4: Mean values of the storage modulus G’ (A), and the dynamic shear
modulus G* (B) at a fixed shear strain of 1.5% over the frequency range of 0.05-1.05
Hz. Samples were tested at compressive strains of 15%, 30%, and 45%, and storage
shear moduli was found to significantly increase with increasing strain.
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3.3.3 In vitro evaluation
The scaffold presented a structure which promoted IVD cell attachment and growth
on the elastic lamellar scaffolds as shown in figure 3.5. Chondrocytes aligned along the
concentric lamellae proving the ability of the scaffold to promote a desired cell response,
as cells in the native IVD are highly aligned along the lamellae. The elastic materials
used to create the scaffold were found to be biocompatible and promoted cellular
proliferation. An alamarBlue® assay was used to determine cell viability on the scaffold
constructs by measuring metabolic activity of the cells. After 19 days in cell culture the
cells proved to remain more viable on the PU scaffold constructs compared to the 2D
culture (figures 3.5 & 3.6). The data presented shows the average of 12 samples ±
standard error of the mean. There was no negative effect on cell viability of the printed
IVD scaffold as compared to the tissue culture polystyrene.

Additionally, scaffold

degradation did not affect cell viability or proliferation since the material we developed
has a degradation profile for 5-6 months. Table 3.2 shows that on days 13, 17, and 19
increased cell proliferation was observed on the PU scaffolds which was significantly
different from the control wells (p<0.05). It should be noted that cell proliferation
decreased after day 15. This is probably due to the fact that the cells had reached
confluence. In some of the control wells, the confluent cells contracted into ball like
structures, possibly limiting the presence of adherent cells on substrates.
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Figure 3. 5: Normalized % reduction graph using AlamarBlue cell metabolic assay
showing cytocompatibility of PU scaffolds (n=12) compared to the control (n=12).
Average of control wells was normalized to 1, and the PU scaffolds were compared at
each day (Annotation ‘*’ indicates samples were statistically significant, p<0.05).
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Figure 3. 6: Chondrocyte viability measured using metabolic AlamarBlue assay.
Comparable proliferation and viability of chondrocytes were found on printed PU IVD
scaffolds and tissue culture polystyrene wells (Annotation ‘*’ indicates samples were
statistically significant, p<0.05).
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Table 3. 2: Statistical analysis for Normalized % Reduction of AlamarBlue Metabolic
Cell Assay for Cytotoxicity (n=12).

Variation
Day 13

Day 17

Day 19

Mean (%) Standard Deviation (%) Significance

PU

106.39

3.97
p<0.05

Control

100

4.19

PU

137.45

3.23
p<0.05

Control

100

1.85

PU

119.45

4.05
p<0.05

Control

100

13.41

3.3.4 Morphological Study
Using our device, elastic polymers were deposited onto a freezing stage using
extrusion to form lamellar structures mimicking the natural structure of IVD tissue as
shown in figure 3.7. Polymer extrusion can be controlled precisely up to a micron level
resolution. Figure 3.2 shows that concentric layers were created with spacing ranging
from 20µm to 200µm for the accommodation of cells while allowing room for
extracellular matrix proteins to be secreted. Additionally, cells preferentially aligned
along the scaffold structure, showing comparable morphology to native IVD cell
alignment within the concentric lamellae (figure 3.7) 22,31.
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A

B

Figure 3. 7: Top view of the scaffold showing viable cells across the entire lamellar
structure, with cells attaching to the entire scaffold (A), inside view of 3-D scaffold,
proving cell infiltration into the inner lamellae (B). It can be seen that spacing can be
accurately controlled to allow the migration of cells into the lamellae. Cells within the
lamellae also aligned with the scaffold. (Scale bar = 100 µm).

3.4 Discussion
The bioprinting apparatus described permitted the use of multiple solution based
polymers and showed the capacity to use both natural and synthetic materials. The
freezing stage allowed for fast solidification of the polymer solution and could maintain
temperatures from -40 °C to room temperature, allowing the rate at which the polymer
solidified to be precisely controlled. The method used in this paper proved the capability
to control both micro and macrostructure of material constructs using computer aided
design. For comparison, the compressive storage moduli of the scaffolds appears to be
sufficient for the repair of the outer region of the IVD as our experimental values (350
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KPa) are within the range of 220-540 KPa previously reported in the literature for native
IVD tissue

29

. However, compressive loads were on the low spectrum of physiologic

values. We expect that when cells grow into the scaffold and will produce extracellular
matrix to further improve the compressive loading capability.

The scaffold created

provides elastic properties while mimicking the natural shape and morphology of the
IVD, as the outer region of the scaffold consists of layered, elastic PU forming concentric
lamellae.
The scaffolds fabricated using this technique exhibited elastic properties which may
help increase natural motion while also absorbing loads within the spine. Dynamic shear
mechanical data was specifically analyzed at 1 Hz because this value is similar to
frequencies observed during common everyday activities. Although frequencies may
increase up to 10 Hz, this is highly uncommon 28,32. Dynamic viscoelastic analysis of the
scaffolds proved the elastic nature of the degradable PU.

For comparison, the

experimental values of G’ (56.7 KPa) and G* (57 KPa) were slightly larger than the
reported native IVD tissue values of 5.8 and 7.4 KPa, respectively

26

. However, the

experimental value of G” (6.5 KPa) was almost identical to the reported value of 5.2 KPa
26

. This analysis leads to the interpretation that the material used here is slightly more

elastic than the native IVD tissue. The cyclic compressive shear moduli of the material
increased with compressive strain and also frequency, proving the effectiveness of the
scaffold to respond to large loads. An increase in stiffness under large stresses is a
common feature of the IVD, possibly preserving disc structure under larger loads to help
maintain cell viability. The primary effect of G’ during shear testing indicates that the
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governing component of this scaffold material is the elastic portion. Values of the loss
tangent (tan delta) were not significantly different between compressive strains,
indicating that the ratio of stored energy to dissipated energy remained relatively constant
at increased strain (data not shown).
Many previous studies have attempted to fabricate a suitable IVD scaffold, but none
have accounted for the complex lamellar structure of the annulus fibrosus in the outer
IVD region. This study uses a specialized biofabrication method to create scaffolds with
very similar structure and overall shape of native IVD tissue. This study also highlights
the importance scaffold microstructure plays in guiding cell behavior through cell-matrix
contact. Chondrocytes seeded onto the scaffolds directly infiltrated into the lamellae.
Eventually, the cells began to elongate along the layers of the scaffold. After 19 days in
culture, the chondrocytes form an aligned cell structure similar to that observed in native
IVD. Throughout this culture period, the scaffolding material did not yet begin to
degrade. Results from cytotoxicity and cell viability assays indicate that this material is
non-toxic and serves as an excellent scaffold choice for further investigations into IVD
regeneration. In another study to evaluate the degradation of our LDI-based PU, we
found that the degradation products are not toxic to cells. This study serves as proof that
the future of IVD tissue engineering will rely on the ability and successes of researchers
to properly design and fabricate scaffolds that satisfy the requirements of matching native
tissue properties with the engineered materials.
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3.5 Conclusion
This is the first study to use a freezing stage to control the resolution of a three
dimensional additive manufacturing device for the fabrication of an IVD scaffold. An
advantage of this technique is the ability to successfully reproduce large quantities of
tissue scaffolds. By combining ultra-fine micropipettes and a freezing stage, the
resolution of the apparatus can be greatly improved. The use of the freezing stage
effectively allows a high resolution design down to the micron level. With the freezing
stage, structure of the scaffold can be controlled precisely allowing for control over cell
morphology. Multiple facets were investigated prior to the creation of the scaffold
including: motor speed, polymer extrusion rate, polymer concentration, and freezing
stage temperature. The spacing between the subsequent layers of the printed elastic
scaffolds is mimetic to the natural IVD and the spacing allows room for cell attachment
while providing space for ECM deposition within the scaffold and ultimately creating a
favorable structure to promote IVD regeneration. The biodegradable PU scaffolds
exhibited superb elastic properties under compression, proving the construct to be an
ideal material for IVD tissue regeneration. Furthermore, during compressive shear testing
at physiological frequencies, the scaffolding constructs behaved similarly to native IVD
tissue, proving their effectiveness to emulate native IVD biomechanics. Future studies
will be carried out over a longer time period to determine how scaffold degradation
affects both cell viability and mechanical properties.
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CHAPTER 4
4. FABRICATION OF AN ELASTIC LAMELLAR SCAFFOLD USING RAPID
PROTOTYPING FOR INTERVERTEBRAL DISC REGENERATION

4.1 Introduction
Low back pain, which affects over 80% of the adult population at some point in
their lives, accounts for 5% of all surgical procedures, amounting to nearly $90 billion in
annual costs 1. One primary cause of low back pain is the degeneration of the
intervertebral disc (IVD), which results in the compression of the spinal nerves and
adjacent vertebrae 2. Exact causes of degeneration are unknown, but it is thought that
natural aging, biological and genetic factors, and mechanical stimuli may play a
significant role in the degenerative process

3-6

. Conventional methods to alleviate this

pain include spinal fusion and artificial disc replacement, neither of which restore natural
kinematics within the spinal column

7-11

.

As an alternative to these conventional

approaches, tissue engineered IVD constructs offer the advantage of biointegration while
preserving the essential attributes of natural motion and disc space restoration. The use of
elastic polymeric artificial discs to mimic the mechanical properties of the native IVD
offer a solution to some of the problems encountered with current disc replacements.
The IVD is the soft and tough fibrocartilage disc that is sandwiched between
adjacent vertebrae in the spine. This tissue functions as: 1) a ligament that holds the
vertebrae of the spine together; 2) a shock absorber; and 3) a “pivot point” that allows the
spine to bend, rotate, and twist. The IVD is composed of three structures: the nucleus
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pulposus (NP), the water-rich gelatinous center that primarily bears the pressure; the
annulus fibrosus (AF), the collagen-rich fibrous structure of 15~25 concentric sheets of
collagen (lamellae) that confines the pressurized nucleus; and the vertebral end-plates
(VEP), which are cartilaginous plates that are interwoven into the annulus at the discvertebrae interface and supply nutrients to the disc 12. Chondrocyte-like disc cells reside
in all three of these structures. The disc is kidney shaped and avascular, making natural
regeneration difficult 13.
The current study focuses on the fabrication of structures that precisely mimic
every facet of the AF, as the complex tissue architecture of this region has posed great
challenges to researchers. This is most likely due to their inability to closely match the
biological function, microstructure, and mechanical properties of the intricate AF. This
region is a lamellar structure composed of collagen type I and II fibers, which maintain
the tensile properties and prevent mechanical bulging of the disc, while also providing
support for cell guidance and proteoglycan synthesis 14. Cells within the AF are oriented
in alignment with the lamellar collagen fibers

15

. It has been shown that cell alignment

can be guided in accordance with a scaffold, as aligned substrates have been shown to
influence cell morphology 16,17. This is highly important for an IVD scaffold, in order to
allow chondrocytes to spread out, align, and organize their cytoskeletons similar as in the
native tissue 18,19. In addition, aligned cells usually generate highly organized ECM in the
direction of cell orientation 18,20. This increase in cell orientation and ECM production on
aligned substrates has also been shown to significantly increase the mechanical strength
of the scaffolds

21

. From this data, it can be seen that a tissue engineered scaffold that
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closely mimics the native architecture of the disc as closely as possible, which contains
highly ordered lamellar layers, would demonstrate a major advancement compared to
current IVD scaffold fabrication methods.
Few scaffold fabrication techniques have allowed for the reproducibility and
spatial control over IVD scaffold design that rapid prototyping permits. However,
electrospun nanofibers and other materials have been created to mimic the AF

22,23

.

These scaffolds do not have the ability to be fabricated in a spatially controlled manner.
Furthermore, few researchers have investigated the fabrication of IVD scaffolds with
similar mechanical properties to the native disc. The mechanical integrity of the IVD is
very important because it aids in maintaining spinal column height. The elastic nature of
the IVD also allows the disc to absorb large compressive loads without permanent
deformation. Therefore, we aim to reproduce an elastic IVD scaffolding material that
better mimics natural IVD morphology and biomechanics.
The scaffold fabrication technology presented here uses a freezing stage coupled
with a custom-made rapid prototyping apparatus to fabricate scaffolds that mimic the
native IVD microstructures with high reproducibility. Additionally, this rapid prototyping
setup enables the creation of patient specific scaffolds to make the technique more
clinically relevant. The device extrudes polymer solution onto a freezing stage to create
scaffolds through a layer-by-layer process, also termed “additive manufacturing”

24-27

.

The freezing stage increases the polymer viscosity and solidifies the solution as it is
extruded out of ultra-fine micropipettes, allowing the device to maintain a high
resolution. In this study, a degradable chitosan/gelatin (Chs/Gtn) solution was used to
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create an IVD scaffold that provides elastic properties, and promotes IVD cell adhesion
and proliferation in alignment with the lamellar region.

In addition to mechanical

properties, the scaffold was designed in CAD to mimic the native AF, forming concentric
lamellae in a kidney-like shape. Currently, we are not aware of any research claiming to
have replicated IVD shape, microstructure, and the mechanical properties of the AF when
fabricating an IVD scaffold or construct.
There is a great need for the development of tissue engineered scaffolds that
simulate the natural 3-D morphology and microenvironment of targeted tissues. Many
researchers have investigated tissue engineering applications to fabricate IVD scaffolds.
However, the majority of studies on IVD tissue regeneration fail to simultaneously
account for both biomechanical properties and natural tissue morphology, both of which
are imperative for the success of an IVD scaffold 28-30. The close correlation between the
biological function and the molecular composition of the disc structures strongly suggests
that a major task of IVD regeneration is to create scaffolds that precisely reproduce the
structural and biological functions of disc structure. In this study, we aim to fabricate
IVD scaffolds with the similar microstructures and mechanical properties as the native
IVD tissue, and prove that tissue regeneration of the IVD is possible.
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4.2 Materials and Methods

4.2.1 Rapid Prototyping Device
A rapid prototyping instrument was developed in our lab in order to fit the
specific needs of this study (Figure 4.1). The motion controlling hardware and software
were specially designed to fabricate scaffolds that mimic the AF region of the IVD.
Microsoft Visual Basic was used to program the controlling software and control the
motors and dispensers. AutoCAD was used to design the scaffolds mimicking the
patterns of IVD lamellae. Micropipettes with 25 µm inner diameter were used as printing
tips. A freezing stage (model BFS-30MP, Physitemp Inc., Clifton, NJ) with a finely tuned
temperature control was used for fast freezing of the dispensed polymer solution into 3-D
structures through layer-by-layer fabrication.
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Figure 4. 1: The home made computer-controlled rapid prototyping apparatus with
temperature-controlled stage for 3-D IVD scaffold printing.

4.2.2 Polymer Synthesis
Light curable, biodegradable, and biocompatible chitosan/gelatin (Chs/GEL)
materials were created using a method developed in our lab for cartilage tissue
regeneration 31. Briefly, 5% gelatin was dissolved in dimethyl sulfoxide (DMSO) and 1%
Irgacure 2959 (obtained from Ciba Specialty Chemicals) was dissolved separately in
DMSO. 75 mg of methacrylate modified photocurable chitosan was mixed with 0.5 mg
of Irgacure solution and added to 1.05 g of the gelatin/DMSO solution and dissolved for

108

10 minutes. The resulting solution was then used to fabricate the IVD scaffolds using the
homemade bioprinter.

4.2.3 Scaffold Fabrication
Scaffolds were designed to replicate the natural IVD shape and histological
morphology, as detailed in the literature (Figure 4.2)

32

. The polymer solution was

dispensed using a syringe pump (Kent Scientific, Torrington, CT) at a flow rate of 0.005
ml/min. The polymer solution was fed through a glass micropipette tip and deposited on
the freezing stage, which was set at 0° C. The approximate build time for each scaffold
layer was around 5 minutes. After printing a layer, the micropipette was raised 50 µm in
the z-direction and continued to lay the next layer. After finishing printing the whole
structure, the freezing stage was powered off and ultraviolet light was exposed to the
printed structure for 10 minutes to further solidify the scaffolds. The scaffolds were then
frozen again and subjected to freeze-drying for 24 hours to extract the solvent. After
lyopholization, scaffolds were rinsed with phosphate buffered saline (PBS) 3 times and
then sterilized in 70% ethanol for 30 minutes, followed by 3 more rinses in sterile PBS.

4.2.4 Isolation and Culture of Chondrocytes on the 3-D Scaffolds
The IVDs of 4 to 5 month old calves were surgically removed and digested in
order to isolate the IVD chondrocytes. The primary bovine IVD chondrocytes were
cultured to passage 2 and then seeded on the scaffolds at a density of 1.25 x 104
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cells/scaffold to examine their growth on the printed constructs. The IVD constructs were
incubated at 37 °C and 5% CO2 for 10 days before fixing in 4% paraformaldehyde and
staining with AlexaFluor 488 Phalloidin (Invitrogen, Carlsbad, CA), for the actin
filaments, and DAPI (Invitrogen, Carlsbad, CA), for the cell nuclei.

4.2.5 Visualization
Scanning Electron Microscopy (SEM, Hitachi TM-1000, Tokyo, Japan) was used
to visualize the morphology of the fabricated scaffold. All microscope images of
fluorescently labeled cells were taken using a Leica TCS SP5 AOBS Confocal
Microscope (Leica Microsystems Inc., Exton, PA). The morphology of the cells was
observed to determine if cells were attached, spread out, and aligned on the 3-D
scaffolds. Images were then compared to native IVD tissue structures from the literature.

4.2.6 Mechanical Testing
Mechanical properties of the scaffolds were characterized using unconfined
compression tests on hydrated samples at room temperature. IVD scaffolds (5.75 mm x
1.75 mm, diameter x height) were compressed at a rate of 1 mm/minute using a Dynamic
Mechanical Analysis (DMA) Q800 system (TA Instruments, New Castle, DE) and
discontinued at 45% strain. As previous studies have shown the IVD to experience
roughly only about 15% compressive strain

33-35

,

compression to 45% accounted for

loading of the scaffolds under extreme conditions. Afterwards, the engineering stress and
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strain were evaluated while the compressive elastic modulus was calculated from the data
of the stress-strain curves. Additionally, unconfined dynamic compression tests were
completed for 7 cycles at a rate of 1 mm/minute over the range of 30-45% compressive
strain. These strains were used as they simulate strains that are slightly larger than normal
physiological loads, which prove the ability of the material to recover under abnormal
conditions

36,37

. Dynamic experiments were also performed on the scaffolds, similar to

previous studies 37. Dynamic confined compression was used to compare the behavior of
the scaffold material with native human IVD tissue at physiological frequencies. Briefly,
5 mm diameter hydrated samples were compressed to 10% strain and then dynamically
compressed with amplitude of 1 µm using a frequency sweep ranging from 0.25 Hz to 5
Hz. This compressive strain and frequency range both simulate normal physiologic
loading conditions within the IVD

33,38,39

. The values of G’ (storage moduli), G’’ (loss

moduli), G* (complex moduli), and tan δ (phase angle) were all recorded and analyzed.
All samples were tested in triplicate and represented as average ± standard deviation. The
load cell readings were recorded on a computer and analyzed with TA Universal Analysis
2000 Software (TA Instruments, New Castle, DE).

4.2.7 Statistical Analysis
One-way ANOVA was performed on the values of G’, G’’, G*, and tan δ across
the frequency range of 0.25 Hz to 5 Hz to compare the IVD scaffolds with the native
human IVD tissues. A least significant difference (LSD) post hoc comparison set at
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p<0.05 was used. SPSS V17 software (Chicago, USA) was used to perform the statistic
analysis.

4.3 Results

4.3.1 Scaffold fabrication
Using the customized 3-D bioprinter (Figure 4.1), elastic Chs/Gtn polymers were
fabricated into lamellar structures mimicking the natural shape (Figure 4.2A) and
microstructure (Figure 4.2B) of the IVD. The video for the high resolution IVD scaffold
printing process can be viewed from the supplemental materials section. The custom
micropipettes enabled the fabrication of scaffolds with high resolution and concentric
layers, having a thickness of 50-100 µm, with spacing of 100-200 µm for the
accommodation of cells (Figure 4.3 & 4.4)

40-42

. The freezing stage allowed for fast

solidification of the polymer solution and maintained the polymer solution viscosity,
making it ideal for scaffold shape retention. In figure 4.3 and 4.4, it can be observed that
cells lined along the scaffold patterns and migrated into the voids between the concentric
lamellae, demonstrating the efficacy of this scaffold in mimicking the structure of the
ECM and guiding the cellular organization of the native IVD. This is confirmed by
comparing the structure of our fabricated scaffolds (Figure 4.4 A&B) with native IVD
tissues (Figure 4.4C).
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A

B

Figure 4. 2: Top-view image of the multilayered IVD scaffold, showing that the
structure mimics the kidney shape and the organization of the concentric lamellar
microstructures of the natural IVD (A). High magnification SEM image of the
Chs/Gtn scaffold lamellae stacked in multiple layers, proving the efficacy of this
technique to create layered structures in 3-D while accurately controlling spacing
between layers, similar to native tissue (B).

A

300 um

B

C

50 um

300 um

Figure 4. 3: Cells aligned along the 3-D Chs/Gtn IVD scaffold structure (A), higher
magnification image showing cell elongation and alignment along lamellar scaffold
(B). Actin filaments and nuclei stained in green and blue, respectively. 3-D rendering
of cells on scaffold from Figure 4.3A (C). Cells and actin cytoskeleton are shown in
grey, while the scaffold is where the empty lamellar channels are located.
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A

B

100 um

C

100 um

Figure 4. 4: Top view of the 3-D scaffold showing aligned IVD chondrocytes inside the
scaffold, demonstrating cell infiltration into the inner lamellae (A), higher
magnification image of cells aligned along lamellae (B), and cells in natural IVD
tissue for comparison (C). Actin filaments are stained green (A-C), while nuclei are
stained blue (A,B), and orange (C). 32

4.3.2 Culture of Chondrocytes on the 3-D Scaffolds
The fabricated constructs resembled the native IVD architecture and shape,
containing a highly ordered outer AF region, while emulating the elastic nature of the
native IVD. Cells grew well on all of the scaffolds, confirming preliminary results
demonstrating excellent biocompatibility

31

. Bovine IVD cells attached, migrated, and

spread uniformly on and within the lamellar scaffolds, while proliferating in three
dimensions (Figure 4.3 & 4.4). The designed 3-D scaffold increased the surface area of
the construct allowing cells to attach and conform to the native tissue architecture. The
cells became elongated and became layered in a concentric fashion similar to the native
AF (Figure 4.3 & 4.4).

This preferential cell alignment exhibited comparable cell

morphology to the lamellae of native IVD tissue (Figure 4.3C) 32,43.
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4.3.3 Biomechanical Analysis
The average compressive elastic modulus for the toe region, at <5% strain, was
0.101 ± 0.03 MPa, while the average elastic modulus for the elastic region, at >15%
strain, was 0.31 ± 0.018 MPa (n=7). A representative stress-strain curve of the scaffold
can be seen in Figure 4.5. There was no evidence that sustained compressive forces
negatively affected scaffold thickness, as no permanent deformation occurred in samples
compressed to 45% strain. This larger strain, compared to the typical 15% compressive
strain that the IVD normally experiences, was used to validate the efficacy of the Chs/Gtn
scaffolds in maintaining its ability to support extreme or abnormal loading 33-35. The IVD,
like other soft tissues, exhibits a J-shaped stress-strain curve similar to the curve shown in
Figure 4.5, representing the Chs/Gtn scaffolds. Elastic hysteresis of the scaffolding
material was observed after dynamic compressive loading, as seen in Figure 4.6. After 3
cycles of preconditioning, repeatable cycles were achieved where the material showed
elastic properties. Scaffolds demonstrated the ability to resist fatigue over time, therefore
proving an excellent choice as a disc replacement material. These results confirm that the
elastic scaffold has ideal properties to absorb forces and recover without experiencing
significant deformation.

The Chs/Gtn scaffolds and native tissue were tested using

dynamic physiological frequencies around 1 Hz across a range from 0.25 to 5 Hz (Figure
4.7). Specifically, G’, G’’, G*, and tan δ were analyzed for both samples, and the results
indicated that the scaffolding material behaved very similar to native human IVD tissues.
As seen in figure 4.7, energy is primarily stored by the material during deformation, as G’
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and G* values between the scaffold and tissue are very similar, demonstrating that native
IVD tissue and the scaffolding material are significantly governed by elastic properties.
No significant difference was seen between the mechanical properties of the native tissue
and scaffolds (Table 4.1), indicating that the scaffolds are suitable for use as an IVD
replacement.

Stress (MPa)
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0.04

Toe Region

Elastic Region

0
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0.3
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0.45

Strain
Figure 4. 5: Representative compressive stress-strain curve showing a J-shaped curve
of the Chs/Gtn IVD scaffold with an initial toe region followed by a linear elastic
region.
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Figure 4. 6: Representative dynamic compressive loading curve of the Chs/Gtn IVD
scaffold. For the displacement of 30% to 45% (A), scaffold size was not altered after
compressing (B), and the scaffolds were able to maintain constant forces, proving that
the Chs/Gtn material is maintaining its elastic integrity (C).
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Figure 4. 7: Graphs showing very similar average G’ (A), G’’ (B), G* (C), and tan δ
(D) of human IVD tissues and IVD scaffolds (n=7). Samples were tested across a
dynamic frequency range from 0.25 to 5 Hz.

Table 4. 1: At a physiological frequency of 1 Hz, there was no significant difference in
mechanical properties (G’, G’’, G*, and tan δ) between the scaffolds and the native
IVD tissues. Data is shown as average ± standard deviation.

Tissues
(n=7)
Scaffolds
(n=7)

Storage
Modulus
(kPa)
401.6 ± 191.8

Loss Modulus
(kPa)

Tangent Delta

77.3 ± 45.1

Complex
Modulus
(kPa)
409.3 ± 196.1

434.8 ± 214.5

85 ± 45.9

443 ± 219.3

0.192 ± 0.016
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0.188 ± 0.055

4.4 Discussion
One hurdle in the field of regenerative medicine is to create a method to fabricate
tissue scaffolds that can be translated clinically for a variety of patients. The rapid
prototyping technology developed here incorporates a customized scaffold design,
enabling the creation of patient-specific tissue engineered constructs. Current disc
replacement strategies do not account for biological growth or integration when
compared to the native IVD. Furthermore, previous scaffold fabrication methods aimed at
overcoming the shortcomings of spinal fusion and the current disc replacements fail to
address the importance of replicating scaffold microstructure and biomechanics.
Therefore, a rapid prototyping approach was developed in which 3-D scaffolds with
morphological, biological, and mechanical properties similar to those of native IVDs
could be produced. This method provides a way for 3-D scaffold formation through
layer-by-layer fabrication in a reproducible and cost effective manner.
A lamellar disc scaffold formed from elastomers would offer much better
compliance and may allow the restoration of natural three dimensional spinal motions
compared to current disc replacement options. The novel scaffold with lamellar structures
closely mimics the histological structure found in the AF portion of native IVDs.
Lamellar structures also allow a greater surface area for cell adhesion and growth.
Currently, many different techniques have been used to fabricate scaffolds for IVD
regeneration; however, few have been able to fabricate the complex lamellar structure
that is unique to natural IVD architecture. The ability of our bioprinted scaffold to mimic
the lamellar pattern, thickness, as well as the spacing between the lamellae within the
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native IVD, corresponds with data supported by the literature for both the layer thickness
as well as the interlamellar spacing

40-42

. Furthermore, this study shows the ability to

guide cell organization on a scaffold mimicking IVD microstructure by controlling
scaffold microstructures. To this end, we used a bioprinting-based rapid prototyping
technique that combines ultra-fine micropipettes for liquid extrusion and a freezing stage
for the fast solidification of the biomimetic scaffolds. As the polymer solutions solidify
rapidly, the scaffold becomes self supporting and supports the addition of new layers and
the creation of 3-D structures. This method is highly valuable as it allows for the use of
many different polymer solutions and can reproducibly create scaffolds with varying 3-D
configurations and definitive microstructures.
The scaffolds created mimic the native IVD structure while promoting cell
attachment and viability. Chondrocytes attached and aligned in the direction of the outer
lamellae, similar as in the native structure of the IVD. When mimicking the highly
organized native IVD, it is important that the lamellar IVD scaffold transforms cells into
an aligned configuration. This aligned configuration will translate into the production of
ECM in alignment with the fabricated scaffold as evidenced by other studies using
oriented substrates to increase matrix deposition 18,19,44. Scaffold images show a structure
in which cells could attach, proliferate, and create ECM necessary for maintaining IVD
function

45-47

. Space for aggrecan production is extremely important in the IVD as their

hydrophilic properties help the disc material retain water and remain healthy and
functional. In addition, cellular synthesis of aligned matrix within the material will
further increase the mechanical properties of the scaffold 21.
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The 3-D elastic Chs/Gtn scaffold showed superb deformability while having the
ability to be press fitted in between the vertebrae. Large compressive stresses can be
achieved without the polymer scaffold material failing. Furthermore, the compressive
moduli of the scaffold correlates with properties of normal IVD tissue reported in the
literature, proving the efficacy of our scaffolds in satisfying native disc biomechanics
requirements

39,48,49

.

Dynamic testing proved that the scaffolds could handle large

deformations, accounting for extreme physiologic circumstances. Additionally, the
material remained elastic under higher physiological frequencies. Dynamic mechanical
data was specifically analyzed at 1 Hz because this value is similar to frequencies
experienced in humans during common everyday activities

50

. These dynamic loading

tests validated these scaffolds as suitable IVD disc replacements, as both the native tissue
and scaffolding material had similar properties as well as were both governed by the
storage modulus (G’).
The IVD has a limited potential to regenerate because it is avascular, making IVD
degeneration a difficult therapeutic target and a challenging task for tissue engineering.
Current surgical remedies to solve the problem of disc degeneration do not address the
need for a regenerative therapeutic based material design. An elastic, degradable polymer
based scaffold that is biocompatible and can preserve natural 3-D kinematics within the
spine is needed. The novel biomaterial scaffold design discussed in this paper mimics the
AF architecture of the native IVD by successfully reproducing the lamellar nature of the
disc. Furthermore, this scaffold is advantageous over other IVD therapies as it replicates
natural IVD tissue biomechanical properties. The technique described utilizes a method
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that may help regenerate the unique IVD structure for future applications by matching
native tissue structure and biomechanics. Also, as this method of rapid prototyping does
not use high temperatures, it allows for drug encapsulation and has the ability to use a
broad variety of biomaterials, making it an ideal candidate for a wide variety of future
applications.

4.5 Conclusion
The development of a computer-aided tissue engineering platform for IVD
regeneration is a challenging task. This study focused on using a rapid prototyping
technique to fabricate IVD scaffolds with similar microstructures and biomechanics to
the native IVD tissues. It was determined that the fabricated scaffolds, in combination
with IVD cells, may be suitable to promote IVD tissue regeneration as they encouraged
cell morphology and arrangement similar to native IVD tissues. In addition, the lamellar
scaffold design and materials exhibited the necessary mechanical properties to match
natural IVD biomechanics.
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CHAPTER 5
5. FULLY CELLULARIZED 3-D TISSUE ENGINEERED CONSTRUCTS FOR
INTERVERTEBRAL DISC (IVD) REGENERATION

5.1 Introduction
Currently an understudied aspect within the tissue engineering realm, research
focusing on intervertebral disc (IVD) degeneration and treatments, has fallen short in
their aims to improve patients’ quality of life. The degenerated IVD, which causes
intense low back pain, has been implicated in significant economic strain throughout the
world.1

Clinical attempts to alleviate this pain, such as discectomy, spinal fusion, and

disc replacements, are far from satisfactory as they focus only on the alleviation of some
symptoms, while failing to address the underlying causes of disc degeneration. To
improve upon conventional clinical strategies, some researchers have begun to
investigate unique approaches towards slowing IVD degeneration or promoting IVD
tissue regeneration.

In the long term, the most ideal approach should involve the

regeneration of IVD tissue. Some current strategies focused towards regenerating IVD
tissue have proven successful in promoting the synthesis of extracellular matrix (ECM)
proteins similar to those present in the native tissue.2,3

However, current attempts

towards regenerating IVD tissue do not accurately mimic the IVD histological
microstructure, specifically the organized lamellar structure within the outer region of the
IVD.
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In order to successfully regenerate IVD tissue, there is a pressing need to fabricate
tissue engineered scaffolds with a similar histological architecture of native IVD tissue.
This is of vital importance, as it is widely known that cells respond to their physical
environment.4 A scaffold with a controlled microstructure has the ability to guide and
control cellular orientation and morphology.5 This is especially important for scaffolds
aimed at regenerating the outer annulus fibrosus (AF) region of the IVD, as it is highly
organized and possesses a concentric lamellar structure.6 Therefore, a scaffold which can
mimic the native lamellar orientation of the native AF region would be able to control
cellular alignment and morphology in accordance with the scaffold structure.
Furthermore, studies have shown that ECM synthesis is controlled by cellular
morphology.7,8 ECM composition as well as its structure, have been demonstrated to be
affected by cell behavior on a tissue scaffold. Therefore, a biomimetic IVD scaffold
should control cellular structure and promote synthesis of ECM with similar orientation
and composition. This ultimately promotes the formation of a tissue structure with
similar characteristics to that of native IVD tissue.
To further expand upon the ability to mimic native ECM tissue histology, a
strategy to create fully cellularized IVD scaffolds would prove to be favorable for tissue
regeneration. The ability to successfully retain seeded cells within a scaffold plays a
critical role in encouraging the formation of a 3-D tissue.9 Cellularized structures are
important due to the fact that they provide a necessary platform to promote the formation
of functionalized, living tissue. Currently, the attempts that have been made to create a
cellularized IVD tissue structure have focused primarily on bioreactor systems, magnetic
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seeding, or stacking of singular layered cell-biomaterial constructs.9-11 However, few
other platforms have been investigated to encourage cellular infiltration within a tissue
scaffold. Therefore, a major task in promoting tissue regeneration is the ability to couple
functional cells within biomaterial scaffolds. A cellularized structure promotes the living
functionality of the biomaterial scaffold for tissue regeneration. Furthermore, it is likely
that cellularized scaffolds will improve tissue formation, as cellularizing a tissue
engineered scaffold in 3-D is required to form 3-D tissues.12,13

Many advances have

been made in creating cellularized tissue scaffolds.14,15 Further, the ability of cells to be
seeded within a scaffold is vital for the creation of 3-D tissue constructs.9

3-D

cellularization better emulates the native tissue environment, promoting regenerated
tissue and synthesized matrix more similar to native tissue.16,17 In this study, we describe
a biofabrication strategy to aid in the rapid formation of a 3-D cellularized tissue
engineered construct. A home-made computer-controlled scaffold bioprinter were used
to fabricate a 3-D scaffold fully mimicking the outer region of native IVD tissue.
Multicellular chondrocyte spheroids were formed robotically using our home-made
multicellular spheroid maker and then patterned robotically within the lamellar voids of
the fabricated IVD scaffold structures. Spheroids were used as they have previously
shown to increase ECM content when compared to singular cells.19 This allowed the
rapid cellularization of the scaffolding construct. The 3-D multicellular spheroids began
to attach and spread within the scaffold lamellae while exhibiting a similar cellular
morphology as in the natural tissue. Additionally, synthesized ECM composition and
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structure within the 3-D cellularized IVD scaffold proved similar to that of the native
tissue.
To address the current issues faced with IVD tissue engineering, we have
developed a unique biofabrication strategy to accurately mimic the histological hierarchy
as well as the biomechanics of native IVD tissue.18 This technique offers the advantage
of computer aided design (CAD), allowing precise control over the shape, as well as the
defined microstructure, of the biomimetic IVD scaffolds.

Using this biofabrication

strategy, it was shown that the lamellar IVD tissue histology could be simulated with the
biomimetic scaffolds.

Further, this approach enables high resolution fabrication of

reproducible scaffolding constructs using a variety of polymeric biomaterials. To take
advantage of the automated process, custom-made robotics were used to fabricate 3-D
multicellular spheroids.

These multicellular spheroids were patterned into the void

lamellar regions of the biomimetic IVD scaffold to create a functional cellularized tissue
structure. It was found that the 3-D cellularized scaffold emulated native IVD cellular
structure as well as ECM matrix composition and structure.

Ultimately, a strategy

similar to the one described here may be used to create a tissue engineered IVD structure
that may be directly implanted into patients to restore natural IVD tissue function.
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5.2 Materials and Methods

5.2.1 Scaffold Fabrication
Scaffolds were fabricated using a home-made computer-controlled bioprinter.
Medical grade polyurethane (PU) was dissolved in DMF at a concentration of 15%. The
solution was then extruded using a 3-D biofabrication device where the scaffold was
designed using AutoCAD (Figure 5.1A). Specifically, the polymer solution was extruded
out through a micropipette-based needle (50 µm diameter) and onto a computer- and
temperature-controlled collecting stage. As the polymer solution was extruded through
the tip, the solution viscosity drastically increased and it solidified instantly, as the
temperature-controlled stage was set below the freezing point of the polymer solution, at
-5° C.

A

B

Figure 5. 1: CAD design of the multilayered scaffold mimicking the overall shape and
morphology of the native IVD tissue (A). Software interface was developed to allow the
designed scaffolds to be printed and monitored during the printing process in real-time
(B).
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5.2.2 Scaffold Characterization
The dimensions and morphology of the printed scaffolds were analyzed using a
JEOL LV-5610 scanning electron microscope (SEM) (JEOL Electronics Inc., Tokyo,
Japan). Specifically, the scaffolds lamellar layers and spacing were verified to match the
lamellae size and spacing of native human IVD tissue. Once this was confirmed, the size
of the spacing between the lamellar layers was assessed.

5.2.3 Multicellular Spheroid Fabrication
In order to develop a truly 3-D, fully cellularized structure for IVD formation, we
used multicellular spheroids as building blocks to seed into the scaffolds. Using the data
obtained from the SEM, it was determined that multicellular spheroids would need to be
fabricated within a very specific size range in order to fit within the lamellae. Bovine
chondrocytes were used to create multicellular spheroids with uniform size using a homemade spheroid maker. The process can be seen in figure 5.2. Briefly, a computeroperated device was used to stamp molten 2% agarose PBS solution until the mold had
hardened. Cell suspensions were added into the agarose molds, and incubated at 37 °C
and 5% CO2 for 48 hours. Cell spheroids were then gathered for positioning into the
scaffold.
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Figure 5. 2: (A) Plastic male-mold used to fabricate agarose microwells, (B-D)
automated robotic stamping of agarose gel by the plastic male-mold, and thus (E)
robotically produced agarose microwells.

5.2.4 Scaffold Cellularization
To seed the scaffolds, multicellular spheroids were pipetted into the prefabricated
scaffolds using a custom-made computer-controlled robotic positioning system. The
chondrocyte spheroids were placed into the void lamellar scaffold spacing using precise
positioning. A schematic of this process can be seen in figure 5.3. To compare the
ability of spheroids to increase 3-D tissue formation, single cells were also seeded into
the scaffolds as a control at the same cell number. The scaffolds were cultured for 4
weeks to create fully cellularized IVD scaffolding constructs. Media was changed and
collected throughout the culture period for further biochemical analysis of secreted ECM.
An inverted microscope (Olympus Co., Tokyo, Japan) was used to monitor cell growth
on the scaffolds.
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Figure 5. 3: Schematic of spheroid deposition within IVD scaffold lamellae.
5.2.5 Biochemical Analysis
After 4 weeks in culture, the IVD tissue scaffolds were evaluated to determine the
ECM content of the constructs. Additionally, the molecules solubilized in the media
supernatant were collected throughout the study to determine the amount of specific
ECM released. All colorometric assays were analyzed using a Synergy H1 Hybrid plate
reader (Biotek, Winooski, VT, USA). To determine the amount of ECM retained within
the scaffolds, the samples were digested: in a papain solution
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overnight at 60 °C for

sulfated-glycosaminoglycan (sGAG) and hydroxyproline quantification, or in pepsin and
elastase digest for 7 days at 4 °C for collagen I and II quantification.

In order to

normalize the amount of newly formed ECM components, DNA content was quantified.
The analyzed sGAG, hydroxyproline, and collagen types I & II quantities (µg) were
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normalized by the average total DNA content (µg) to enable comparison between sample
groups. Additionally, the hydroxyproline content was normalized to sGAG to compare
sample groups with values similar to native cartilage tissue. The scaffolds seeded with 3D multicellular spheroids (experimental group) were compared to scaffolds seeded with
single cells (control).

5.2.5.1 DNA Quantification
In order to normalize the biochemical data between each test group, the DNA
content within each scaffold group was analyzed using a DNA Quantitation Flourescent
Assay Kit (Sigma-Aldrich, St.Louis, MO, USA).21 Briefly, 25 µL of cell digest solution
in papain was combined with 200 µL of Hoeschst dye (2 µg/mL). Standard curves were
created using calf thymus DNA. Fluorescence was read at 360 nm excitation and 460 nm
emission.

5.2.5.2 sGAG Synthesis
Cellular production of sGAGs was analyzed using 1,9-Dimethyl-Methylene Blue
(DMMB) salt (Sigma-Aldrich), similarly to techniques used by others.22 Briefly, 16 mg
of DMMB was dissolved in 1 L of distilled water containing 3.04 g glycine, and 2.37 g
NaCl and stirred overnight. This was followed by the addition of 95 mL of 0.1 M HCl to
give a pH of 3.0. The solution was stored at room temperature and away from light. 50
µL samples of cell digest solution in papain were then transferred into a flat bottom 96
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well plate (Greiner Bio-One, Frickenhausen, Germany) containing 200 µL of DMMB
reagent per well. The absorbance was read at 525 nm. Standard curves were created
using chondroitin sulfate from shark cartilage (Sigma-Aldrich) with a linear
concentration ranging from 0-100 µg/mL.

5.2.5.3 Hydroxyproline Formation
The total amount of collagen was analyzed using a hydroxyproline assay kit
(Sigma-Aldrich), as hydroxyproline has been previously defined as a marker for overall
collagen production.23,24 Briefly, 100 µL samples of cell digest solution in papain were
hydrolyzed in the presence of 12 M HCl at 120 °C for 3 hours followed by evaporation of
the samples. Samples were reacted with Chloramine T for 5 minutes followed by an
incubation with 4-(Dimethylamino)benzaldehyde (DMAB)for 90 minutes. Standard
curves were created using the provided hydroxyproline standard. The absorbance was
then read at 560 nm.

5.2.5.4 Collagen Types I & II Synthesis
After evaluating hydroxyproline content, additional biochemical analysis was
needed to determine and quantify which types of collagen were present. Specifically,
collagen types I & II were chosen for an enzyme-linked immunosorbent assay (ELISA)
analysis as they are the most prevalent collagens in the IVD. Chondrex ELISAs for both
collagen types I & II (Chondrex, Inc., Redmond, WA, USA) were used and the relevant
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protocols were followed.

Briefly, capture antibodies were added to 96 well plates

overnight, followed by a 2 hour incubation of the pepsin and elastase digested samples.
Detection antibodies were then added for 2 hours followed by the addition of streptavidin
peroxidase for 1 hour. Then, the OPD chromagen was added for 30 minutes followed by
the addition of 2N sulfuric acid to stop the reaction. Collagen samples were compared
against collagen standards and absorbance was read at 490 nm for both collagen types I
& II.

5.2.6 Immunohistochemistry
Cellularized constructs were fluorescently analyzed to evaluate the presence and
structure of collagen types I & II, and to visualize the cell nuclei. Nuclei were stained
with DAPI (blue), while collagens were stained using secondary antibodies (collagen
type I: green, collagen type II: red). Briefly, cellularized constructs were fixed in 4%
paraformaldehyde and blocked using 4% goat serum. Rabbit anti-bovine collagen type I
polyclonal antibody (Millipore, Bedford, MA, USA) was added overnight followed by
rinsing three times and the addition of Cy2-conjugated goat anti-rabbit IgG (Jackson
ImmnoResearch, West Grove, PA, USA) and subsequent washing. This was repeated for
the mouse anti-collagen type II monoclonal primary antibody (Millipore) and the Cy3conjugated goat anti-mouse IgG (Jackson ImmnoResearch) followed by washing. DAPI
(Invitrogen, Carlsbad, CA, USA) was then used similarly to fluorescently label cell
nuclei within the scaffold constructs. Samples were observed using a Fluoview-FV1000
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laser scanning confocal microscope (Olympus) to qualitatively analyze 3-D
cellularization of the scaffolds and subsequent ECM formation.

5.2.7 Statistical Analysis
Data were expressed as mean ± standard error of mean. An independent-sample
t-test was performed on all biochemical analyses to compare the two IVD scaffold
groups: 1) control scaffolds seeded with single cells, 2) experimental scaffolds seeded
with multicellular spheroids. Significance was determined at p<0.05. SPSS V17 software
(Chicago, IL, USA) was used to perform the statistic analysis.

5.3 Results

5.3.1 Scaffold Structure
Utilizing our layer-by-layer and temperature controlled biofabrication strategy,
reproducible multilayered 3-D scaffolds mimicking native IVD structures were easily
fabricated. The overall shape and structure of the native IVD was extensively studied in
order to design biomimetic scaffolds with similar properties using AutoCAD. A unique
concentric lamellar structure was created, with each layer having a thickness of 50 µm
and the spacing between each concentric lamellae at 175 µm. This structure can be
observed in the SEM image in figure 5.4, where the uniform and layered structure is
highly apparent.
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A

B

Figure 5. 4: Overall image showing scaffold size and shape (A). SEM image showing
multilayered scaffold structure with highly uniform and concentric lamellar layers
mimicking native IVD structure (B).
5.3.2 Spheroid Properties
Using the robotic spheroid maker, highly uniform spheroids were fabricated with
precise diameters of 125 µm using cell seeding densities of 1.3 x 104 cells/agarose mold
(Figure 5.5). This size proved optimal as it enabled the spheroids to be easily extruded
into the lamellar voids of the scaffolds, which were slightly larger than the spheroid
diameter.
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250 µm

Figure 5. 5: Multicellular chondrocyte spheroids in culture within microwells,
demonstrating a highly uniform diameter of 125 µm.
5.3.3 Scaffold Cellularization
After seeding, spheroids appeared to fully integrate within the scaffold lamellae.
The multicellular spheroids began to fuse days after initial seeding. After 1 week, the
spheroids are fused and fully integrated with the scaffolds and formed 3-D tissues. The
single cells attached to the scaffolds and covered the entire structure, however, they failed
to fully cellularize the lamellar voids as compared to the multicellular spheroids. In the
case of both the single cells and the multicellular spheroids, the cells within the lamellar
voids oriented themselves in alignment with the lamellar scaffold structure.

5.3.4 Biochemical Analysis
The production of ECM by the tissue engineered constructs was identified by
evaluating the amount of sGAG, hydroxyproline, and collagen types I & II in each
sample after 4 weeks. A summary of the synthesized ECM composition retained within
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the scaffolds can be seen in Table 1. Additionally, a summary of ECM released within
the media supernatant is given in Table 2. The data is normalized to mean DNA content.

Table 5. 1: Synthesized ECM within Scaffold after 4 weeks (Mean ± Standard Error of
Mean). *p<0.05

Spheroids
Single Cells

GAG (µg)
/ DNA (µg)

Hydroxyproline
(µg) / DNA (µg)

GAG (µg) /
Hydroxyproline (µg)

Col I (µg) /
DNA (µg)

Col II (µg)
/ DNA (µg)

119.8 ±
2.7*
54.4 ± 3.6

8.4 ± 1.1*

11.9 ± 1.4*

4.6 ± 0.9*

3.8 ± 0.1*

5.5 ± 0.4

8.3 ± 0.6

1.6 ± 0.2

1.8 ± 0.1

Table 5. 2: Synthesized ECM Released in Supernatant after 4 weeks (Mean ± Standard
Error of Mean). *p<0.05
GAG (µg) / DNA (µg)
Spheroids

141.4 ± 11.1

Single Cells

Col I (µg) / DNA (µg)

*

3.74 ± 1.0

108.9 ± 6.0

Col II (µg) / DNA (µg)

*

1.0 ± 0.3

2.6 ± 0.3*
1.1 ± 0.1

5.3.4.1 sGAG Synthesis
The amount of sGAG (spheroids 119.8 ± 2.7 µg/µg, versus single 54.4 ± 3.6
µg/µg) retained within the construct was significantly greater in the scaffolds seeded with
multicellular spheroids compared to the single cell controls, as shown in Figure 5.6A
(n=7 per group, p<0.05). Additionally, as shown in Figure 5.7A, the quantity of sGAG
(spheroids 141.4 ± 11.1 µg/µg, versus single 108.9 ± 6.0 µg/µg) released into the
supernatant was also significantly greater in the scaffolds seeded with multicellular
spheroids compared to the single cell controls (n=7 per group, p<0.05).
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5.3.4.2 Hydroxyproline Formation
Hydroxyproline (spheroids 8.4 ± 1.1 µg/µg, versus single 5.5 ± 0.4 µg/µg)
quantity was significantly greater in the scaffolds seeded with spheroids versus the single
cells as seen in Figure 5.6B (n=7 per group, p<0.05). Additionally, the
GAG/hydroxyproline ratio (spheroids 11.9 ± 1.4 µg/µg, versus single 8.3 ± 0.6 µg/µg)
was also significantly greater in the scaffolds seeded with multicellular spheroids as seen
in Table 1 (n = 7 per group, p<0.05).

5.3.4.3 Collagen Types I & II Synthesis
The amount of collagen type I (spheroids 4.6 ± 0.9 µg/µg, versus single 1.6 ± 0.2
µg/µg) retained within the construct was significantly larger in the scaffolds seeded with
spheroids versus the single cell control as seen in Figure 5.6C (n = 7 per group, p<0.05).
Similarly, as shown in Figure 5.6D, the amount of collagen type II (spheroids 3.8 ± 0.1
µg/µg, versus single 1.8 ± 0.1 µg/µg) preserved within the scaffold was significantly
larger in the experimental group with multicellular spheroid seeded scaffolds (n = 7 per
group, p<0.05). Figure 5.7B shows that the quantity of collagen type I (spheroids 3.74 ±
1.0 µg/µg, versus single 1.0 ± 0.3 µg/µg) released into the supernatant was significantly
greater in the scaffolds seeded with spheroids versus the single cell control (n = 7 per
group, p<0.05). This was also observed for the amount of collagen type II (spheroids 2.6
± 0.3 µg/µg, versus single 1.1 ± 0.1 µg/µg) released into the media was significantly
larger in the experimental group with multicellular spheroid seeded scaffolds compared
to the single cell controls as shown in Figure 5.7C (n = 7 per group, p<0.05).
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Figure 5. 6: Results from biochemical analysis of ECM within the scaffolds
cellularized with cell suspension and spheroids after 4 weeks. Statistical analysis
comparing groups showed significant differences for all study groups (n =7 for each
group, *p<0.05). The sGAG (A), hydroxyproline (B), collagen type I (C), and collagen
type II (D) content was all significantly greater in the scaffolds cellularized with
sperhoids than with the same number of cells seeded in the format of cell suspension.
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Figure 5. 7: Results from biochemical analysis of ECM released from scaffolds
cellularized with cell suspension and spheroids over 4 weeks. Statistical analysis
comparing groups showed significant differences for all study groups (n =7 for each
group, *p<0.05). The sGAG (A), collagen type I (B), and collagen type II (C) release
was all significantly greater in the scaffolds cellularized with sperhoids than with the
same number of cells seeded in a single cell suspension.

5.3.5 Immunohistochemistry
Image analysis provided qualitative evidence that the synthesized collagenous
ECM was fully integrated within the voids of the lamellar structure in a similar fashion to
native IVD tissue. Further, cells as well as ECM, were organized in a 3-D configuration.
The cell suspension (control) seeded into the biomimetic scaffolds synthesized some
collagenous ECM, but cells only attached to the scaffold surface and failed to synthesize
enough ECM to fill in the lamellar void (Figure 5.8A-D).

A side projection view

showing that the seeded cells in suspension attached to the scaffold surface and secreted
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extracellular molecules, but failed to secrete biomolecules occupying the lamellar void
space as the matrix only accumulated on the scaffold surface as shown in figure 5.8E-H.
On the other hand, the multicellular spheroids fully infiltrated the scaffold lamellae and
grew in a 3-D fashion that enabled the creation of a completely cellularized IVD
construct. Further, staining of collagenous ECM within the lamellae appeared to be
much greater in the scaffolds seeded with spheroids versus single cells, as synthesized
matrix can be seen throughout the entire lamellar voids (Figure 5.8I-L).

A side

projection view proving that the multicellular spheroids fully cellularized the lamellar
void and synthesized a 3-D collagenous matrix throughout the construct can be seen in
figure 5.8M-P.
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Figure 5. 8: Fluorescent images showing chondrocyte growth and ECM synthesis in
the scaffolds. An overview of the cell suspension controls seeded onto the scaffold
after 4 weeks can be seen in: (A) nuclei, (B) collagen type II, (C) collagen type I, and
(D) merged image. A side projection view of the single cells on the scaffold shows that
the cells were superficially adhered to the scaffold surface and did not cellularize the
lamellar region while only producing ECM along the scaffold surface: (E) nuclei, (F)
collagen type II, (G) collagen type I, and (H) merged image.
In comparison, an overview of the spheroids seeded onto the scaffold shows that the
entire construct is cellularized with large quantities of ECM produced : (I) nuclei, (J)
collagen type II, (K) collagen type I, and (L) merged image. A side projection view of
the spheroids within the scaffold further validates that the spheroids have cellularized
the lamellar void and have produced ECM in a 3-D manner: (M) nuclei, (N) collagen
type II, (O) collagen type I, and (P) merged image. The dotted zone in (H) and (P)
shows the lamellar scaffold structure.
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5.4 Discussion
The field of tissue engineering aims to regenerate living tissue that possesses a
similar structure and function to the natural healthy tissue, with the ultimate goal of
replacing the targeted diseased tissue. Tissue engineering often utilizes scaffolds as a
template to guide cell growth and tissue formation. The structure of tissue engineered
scaffolds is important as it not only dictates the mechanical integrity of the construct, but
also guides cell behavior and function as well as new ECM organization. For these
reasons, it is important for the scaffold structure to closely mimic the native tissue
architecture in order to successfully regenerate the native tissue. The corresponding
structure will control cell behavior, and ultimately cellular function. Due to current
limitations in achieving a cell-based functional scaffold that simulates the native tissue,
an approach was developed to provide a fully cellularized-construct for IVD tissue
regeneration.
First, biomimetic IVD scaffolds were fabricated using a novel biofabrication
approach that allowed for the creation of a scaffold with an overall morphology and
microstructure which strongly resembles the architecture of the native IVD tissue.
Advantages of our scaffold over other methods currently being investigated is the use of
an organized lamellar structure, which is more similar to native collagen fibril structure
present in the IVD.25 Our fabricated scaffold had the ability to mimic the structure, layer
thickness, and interlamellar spacing of the native human IVD, as similar values have
been reported in the literature for these characteristics.26-28 As discussed above, by
closely mimicking this structure we believe we will be able to more effectively
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regenerate a tissue construct that is highly similar to native IVD tissue, which has been
identified as a major challenge in tissue engineering the IVD.29 Further, the interlamellar
spacing provided by our scaffolds will allow for cell infiltration and ECM organization.
The novel biofabrication approach discussed above, along with a robotic seeding
strategy, allowed for the ability to organize cell density and distribution within the tissue
scaffold, directly controlling the capacity to form 3-D tissue engineered constructs.
Typically, after seeding cells onto a 3-D scaffold, it is difficult for cells to further fill up
the whole volume of the scaffold and the cells end up adhering only to the scaffold
surface.20,30

This results in a tissue engineered scaffold that is not entirely or

homogenously cellularized due to the decreased cell content within the void regions.
Furthermore, the majority of studies involving cell-biomaterial constructs use single cells
or cell suspensions where cells are only able to adhere to the surface of the scaffold
material and pore walls. Therefore, these seeding techniques are not able to actually
cellularize the whole pores or voids themselves within the constructs. A major issue with
the use of single cells in these applications is a low cell retention within the constructs.31
To circumvent these issues, 3-D multicellular spheroids were fabricated to have a slightly
smaller diameter than the lamellar voids of the fabricated IVD scaffolds.

The

chondrocyte spheroids were then deposited into the lamellar voids where they attached to
the scaffold lamellae and aligned along the structures in a 3-D fashion similar as in the
native tissue. Single cells were seeded onto the IVD scaffold as controls. It was found
that this unique strategy of incorporating spheroids within the scaffold provides an
efficient and quick 3-D cellularization of the construct, which has been described as a
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major challenge.9 Further, after initial seeding, cell spheroids began to fuse together
followed by cellular adhesion to the scaffold. Eventually, the spheroids formed a 3-D
cell layer which was entirely homogenous, avoiding challenges met by others attempting
to cellularize 3-D scaffolds.32 Furthermore, the spheroids synthesized ECM throughout
the scaffold voids, comparable to the matrix formed within the natural IVD, while the cell
seeded by suspension only produced matrix on the scaffold surface.
Multicellular spheroids showed excellent ingrowth within the lamellar voids of
the IVD scaffolds, which led to a more uniform distribution of cells within the 3-D
structure. Further, it appears that these spheroids encouraged organized tissue formation,
with the production of ECM such as collagens and GAGs, within the lamellar spacing of
the scaffold. As expected, larger values for retained ECM components were obtained
with the cellular spheroids as they aided in the preservation of more ECM components.
This is similar to what others have observed.33,34 Specifically, the values we observed for
GAG content within the spheroid cellularized scaffold are within values reported by
others for native cartilage tissues and also tissue engineered constructs.33,35-40
Additionally, our data regarding the GAG/Hydroxyproline ratio correlates well with other
studies involving cartilage and IVD tissue, with values between 2:1 and 27:1.41 Based on
the observed hydroxyproline levels, indicative of overall collagen content, and further
biochemical analysis of specific collagen types, it is evident that collagen types I & II are
the major constituents of the collagenous ECM within the IVD constructs. Further, the
collagen content within our structures is also similar to what others have reported for
tissue engineered constructs.42 Our results showed similar amounts of collagen types I &
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II, though, there were larger overall quantities of collagen type I as compared to collagen
type II. This ratio is similar to that seen in the AF region of the IVD tissue, which this
scaffold aims to replace.43
We believe that the reason the scaffolding constructs seeded with spheroids
retained more matrix is because they provided a 3-D platform for cell growth while
promoting the synthesis and entrapment of matrix more similar to that of native tissue.
As seen in the results, there was not only a significant increase in the amount of ECM
production within the scaffolds cellularized with spheroids, but also a significant increase
in the amount of ECM released into the supernatant. We believe that the scaffolds seeded
with spheroids produced and released more ECM due to the 3-D cell morphology of the
spheroids within the scaffold lamellae, which better mimics the native tissue atmosphere.
The 3-D cellular and matrix interactions provided by the spheroids more closely emulates
the native tissue environment.44 However, the increase in matrix production in the
spheroid cellularized scaffolds may be due to the fact that a more hypoxic environment
was created, as nutrient diffusion to the cells within the spheroids may be decreased.
Many studies have shown an increase in ECM synthesis (GAGs and collagens) when
chondrocytes are placed in a hypoxic environment, more similar to that of native IVD
tissue.45-49
Upon

further

examination

of

the

3-D

tissue

engineered

constructs,

immunostaining showed uniform cell distributions throughout the entire thickness of the
spheroid cellularized scaffolds when compared with the single cell scaffolds.
Subsequently, ECM deposition was also found throughout the scaffold thickness in the
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spheroid seeded scaffolds. Collagen type I staining appeared to mimic the scaffold,
especially in the scaffold cellularized with spheroids, perhaps proving that the ECM was
indeed mimicking the scaffold structure. Further, collagen type II showed up throughout
the voids within the lamellar scaffold. These results show that multicellular spheroids
better integrate within the IVD scaffold than cells from suspension and synthesize
functional tissue in a similar fashion to native IVD tissue.

5.6 Conclusion
This study is the first of its kind attempting to fabricate a fully cellularized 3-D
tissue construct for IVD tissue regeneration. The purpose of this study was to create a
unique IVD scaffold which provided the ability to create a homogenous cell distribution
throughout the structure. This improved upon current cell seeding methods by creating a
fully cellularized scaffold environment with similar matrix compositions to that of native
IVD tissue. The techniques described in this paper are not limited to an IVD scaffold,
and have the ability to be applied to various tissue scaffold technologies. It is our hope
that in the future this approach could be used, in certain applications, to replace
conventional 2-D culture methods by providing a more native 3-D physiological
environment for cells.
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CHAPTER 6
6. OVERALL CONCLUSIONS AND FUTURE DIRECTIONS

6.1 Conclusions
The major impact of this work is in the development of a new technology useful in the
biofabrication of tissue engineering scaffolds, especially for the fabrication of scaffolds
for IVD tissue regeneration. This technology is based upon a custom-made additive
manufacturing platform which enables the precise deposition of polymeric biomaterials
to form structures with similar microstructures and mechanical properties to the targeted
native tissue.

Preliminary studies revealed the potential of the fabricated scaffold

structures to improve upon current IVD scaffold fabrication technologies.

Detailed

conclusions are summarized below, by chapter.

Chapter 3: A novel technology was developed which utilized unique additive
manufacturing techniques.

This technology allowed for the extrusion of polymeric

solutions into 3-D scaffold structures that more closely mimicked the morphology and
structure of native IVD tissue. This was accomplished by extruding a polymeric solution
through micropipettes onto a temperature-controlled collecting platform. By precisely
controlling the temperature of the solution, the device enables the precise control of the
polymeric deposition and allows the solution to be directly solidified due to the drastic
decrease in temperature and subsequent increase in polymer solution viscosity.
Evidence was provided for the ability of this biofabrication platform to utilize various
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polymer solutions. Biocompatible and biodegradable polyurethane (PU) was used for
this study. It was determined that the fabricated IVD scaffolds had a unique shape and
microstructure, which was highly similar to the native tissue structure, and unlike any
tissue scaffold developed to date.

Further, scaffolds demonstrated favorable

biocompatibility and mechanical properties, indicating that they could serve as an
excellent approach for use in IVD tissue regeneration applications.

Chapter 4: Within this chapter, an extension of the previous study is presented. It was
demonstrated that the custom-developed biofabrication strategy could be used with
multiple polymeric solutions to broaden its impact on the ability to create clinically
relevant scaffolds for IVD tissue regeneration. Specifically, an ultraviolet (UV) curable
chitosan-gelatin (Chs/Gtn) material developed in our lab was extruded using the same
fabrication method previously described. The scaffolds’ overall shape and microstructure
proved to mimic the native IVD tissue and histological ECM structure. Further, it was
shown that the IVD scaffolds’ lamellar size and spacing could be accurately controlled to
fabricate biomimetic IVD scaffolds. Cellular behavior, specifically cell alignment in
accordance with the scaffold, was analyzed and compared to native tissue. Results
indicated that the scaffolds had the capability to control cellular morphology similar to
that of native tissue.

Additionally, the mechanical properties of the scaffold were

evaluated. It was demonstrated that the scaffolds’ elasticity as well as dynamic stability
were highly similar to that of native IVD tissue.
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Chapter 5:

In this experiment, the biofabricated IVD scaffold structures were

extensively evaluated in vitro.

To further validate the advances in our scaffold

fabrication process, the ability to create 3-D cellularized IVD scaffolds was thoroughly
investigated. The unique aspects of biofabrication were fully utilized within this study,
as 3-D multicellular spheroids were first created using a novel robotic approach, followed
by their positioning within the biofabricated scaffolds’ lamellae. The spheroids provided
a 3-D platform for the cells to adhere and grow within the scaffold material. Further, the
newly formed ECM was analyzed and proven to exhibit a highly similar structure and
composition to native IVD tissue. This study shows the potential of biofabrication to
provide unique solutions towards the creation of a 3-D cellularized structure for tissue
regeneration.

6.2 Limitations & Challenges
Biomimetic IVD scaffolds for tissue regeneration were successfully created using novel
biofabrication technologies presented in this dissertation. These scaffolds demonstrated
very promising in vitro results. However, several challenges had to be overcome, with
some still remaining, before having the ability to develop a more functional and clinically
relevant engineered IVD scaffold for tissue regeneration. Some of these challenges are
discussed and arranged by chapter below.

Chapter 3: A biofabrication method was presented revealing the ability to successfully
create lamellar scaffolds for IVD tissue regeneration. The major challenge that had to be
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overcome when fabricating the scaffolds was troubleshooting and optimizing the
fabrication parameters of the custom-made device. We needed to investigate motor
speeds, polymer solution viscosity, polymer extrusion rate, freezing temperature, and
micropipette extrusion diameter.

Once these parameters were determined, issues

involving ambient humidity and solvent evaporation still arose as the scaffold fabrication
process depends on precisely controlled conditions. During mechanical testing of the
fabricated structures, it was determined that the mechanical properties of the PU scaffolds
were far from ideal. Even though the elastic modulus was within the lower values
reported for the human IVD, it is our belief that the scaffolds may need to be altered to
improve their mechanical strength.

Chapter 4: Different polymeric solutions were utilized in this study to prove the ability
of the biofabrication method to take advantage of the beneficial properties of various
biomaterials. However, in order to ensure the effectiveness of using the new biomaterial
solutions, the biofabrication parameters had to be optimized once again. Although the
mechanical properties were significantly improved using the Chs/Gtn material compared
to the PU used in chapter 3, there is still room for improvement of the mechanical
stability of the structure in order to create a clinically relevant IVD tissue replacement.

Chapter 5: 3-D multicellular spheroids were used as building block to form a fully
cellularized tissue structure. While the spheroids were easily positioned into the voids of
the lamellar spacing and providing a feasible 3-D platform for 3-D tissue formation, the
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cells were not able to migrate into the lamellar scaffold material due to the low porosity.
We plan to advance the fabrication process by incorporating a porogen during the
scaffold fabrication process so that cells can penetrate into the whole scaffold.

6.3 Future Goals
The ultimate goal of this project was to develop a unique biofabrication based
technology for use in the creation of advanced functional scaffolds for IVD tissue
regeneration. The immediate goals will be to address the challenges listed above while
expanding upon the technologies developed here to improve the scaffolds. In the larger
scheme, this biofabrication technology can be elaborated upon to fabricate better IVD
scaffolds as well as other types of scaffold structures for various types of tissue in the
body. Future plans and goals are summarized below.
One future objective is to advance the biofabrication platform to improve cellular
response. The aim is to aid in the adhesion of the multicellular spheroids to each other,
which may be accomplished by coating the spheroids in ECM protein or ECM-derived
peptides, such as fibronectin, prior to extrusion within the scaffold lamellae. This would
aid in cell fusion and create an entirely cellularized structure.
As for improving the tissue regeneration response to the biofabricated IVD
strategy, we plan to control the differentiation of mesenchymal stem cells (MSCs) into
IVD cell phenotypes by incorporating signaling molecules into and within the scaffold
using nano-layer-by-layer (nanoLBL) technology as well as nanoparticle-based delivery.
These techniques can be used to create a spatial and temporal release profile from the
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IVD scaffold.

Therefore, MSC differentiation can be regionally controlled using

different combinations of biomolecules to produce specific cell lineages within the IVD.
We have already discovered candidate signaling molecules to encourage stem cell
migration and proliferation within the scaffold. In vitro studies analyzing the release
kinetics of these molecules will then be performed.

This will enable optimized

differentiation cocktails to be created for each IVD region which support gene expression
similar to native IVD tissue. The current challenges discussed above are being addressed
to improve the biofabrication strategy.
Finally, the ultimate goal of this project is to assess in vivo growth of IVD tissue
by using these signaling molecules in combination with the biomimetic IVD scaffold to
recruit endogenous stem cells and control their proliferation and IVD phenotypic
differentiation. With the proper combination of signaling molecules, the scaffolds will
recruit endogenous stem cells and encourage proliferation, chondrogenic differentiation,
and synthesis of ECM similar to that of native IVD tissue. Scaffolds will first be created
with immobilized signaling molecules, followed by implantation and histological
evaluation in subcutaneous rodent models. We also aim to assess the regenerated tissue
by evaluating the mechanical properties and comparing those values to native IVD tissue.
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